{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00019878", "CSN": null, "TRF": "ORD_1336448_02", "MRN": "43982770", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1097561", "clinicalId": "1098932", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1336448_02", "SampleName": "US1284630.01", "Version": "0", "Sample": {"FM_Id": "ORD_1336448_02", "SampleId": "US1284630.01", "BlockId": "S111-07951A", "TRFNumber": "ORD_1336448_02", "TestType": "FoundationOne Heme", "SpecFormat": "FFPE", "ReceivedDate": "2022_04_04", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "7010 Kit Creek Road, Morrisville, NC 27560", "cliaNumber": "34D2044309", "locationID": "2", "locationName": "RTP", "processID": "2", "processName": "Extracted DNA"}]}, "TumorPurity": "40", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-99076", "MRN": "43982770", "FullName": "\u6797\u7f8e\u8fb0", "FirstName": "Mei_Chen", "LastName": "Lin", "SubmittedDiagnosis": "Malignant tumor, Anterior lower gingiva", "Gender": "Female", "DOB": "1981_01_30", "OrderingMD": "\u9673\u5929\u83ef", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Mouth", "CollDate": "2022_02_23", "ReceivedDate": "2022-04-21 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Sarcoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "73", "clinicalTrialCount": "17", "resistiveCount": "0", "sensitizingCount": "12"}, "VariantProperties": {"VariantProperty": [{"geneName": "ABL1", "isVUS": "true", "variantName": "S1007*"}, {"geneName": "ALK", "isVUS": "true", "variantName": "E201Q"}, {"geneName": "ARID2", "isVUS": "true", "variantName": "H48Y"}, {"geneName": "ASXL1", "isVUS": "true", "variantName": "I980N"}, {"geneName": "BCORL1", "isVUS": "true", "variantName": "D77N,T1111M"}, {"geneName": "BRCA1", "isVUS": "true", "variantName": "G1232L"}, {"geneName": "BRD4", "isVUS": "true", "variantName": "E657Q"}, {"geneName": "BRIP1", "isVUS": "true", "variantName": "R814C"}, {"geneName": "CD22", "isVUS": "true", "variantName": "S105N"}, {"geneName": "CIC", "isVUS": "true", "variantName": "A531T"}, {"geneName": "CIITA", "isVUS": "true", "variantName": "A462S,A648E"}, {"geneName": "EPHA5", "isVUS": "true", "variantName": "E881D,T176A"}, {"geneName": "EPHB1", "isVUS": "true", "variantName": "I236M"}, {"geneName": "ERBB4", "isVUS": "true", "variantName": "A345V,D1131Y,P1132H"}, {"geneName": "FAM123B", "isVUS": "true", "variantName": "G327C"}, {"geneName": "FBXO11", "isVUS": "true", "variantName": "S34N"}, {"geneName": "FBXO31", "isVUS": "true", "variantName": "R19P"}, {"geneName": "FLT4", "isVUS": "true", "variantName": "A634D,Y435C"}, {"geneName": "FRS2", "isVUS": "true", "variantName": "P240S"}, {"geneName": "GPR124", "isVUS": "true", "variantName": "R369Q"}, {"geneName": "HGF", "isVUS": "true", "variantName": "G31*"}, {"geneName": "HIST1H1C", "isVUS": "true", "variantName": "E3K"}, {"geneName": "HIST1H3B", "isVUS": "true", "variantName": "A92P"}, {"geneName": "IL7R", "isVUS": "true", "variantName": "K104N,L123V"}, {"geneName": "JUN", "isVUS": "true", "variantName": "R221Q"}, {"geneName": "LRP1B", "isVUS": "true", "variantName": "S1198Y,S913R"}, {"geneName": "MAPK1", "isVUS": "true", "variantName": "D210H"}, {"geneName": "MKI67", "isVUS": "true", "variantName": "I2578V"}, {"geneName": "MYST3", "isVUS": "true", "variantName": "A1442S,P1766L"}, {"geneName": "NOTCH1", "isVUS": "true", "variantName": "P1884Q"}, {"geneName": "NSD1", "isVUS": "true", "variantName": "R1074L"}, {"geneName": "NTRK2", "isVUS": "true", "variantName": "A187E"}, {"geneName": "P2RY8", "isVUS": "true", "variantName": "P341H"}, {"geneName": "PCLO", "isVUS": "true", "variantName": "E3034D,P995A"}, {"geneName": "PDGFRA", "isVUS": "true", "variantName": "A7P"}, {"geneName": "PLCG2", "isVUS": "true", "variantName": "E1208K"}, {"geneName": "POT1", "isVUS": "true", "variantName": "T425A"}, {"geneName": "PPP2R1A", "isVUS": "true", "variantName": "V259F"}, {"geneName": "PRKDC", "isVUS": "true", "variantName": "D3411H"}, {"geneName": "SMARCA4", "isVUS": "true", "variantName": "D1183Y"}, {"geneName": "SMC3", "isVUS": "true", "variantName": "E998*"}, {"geneName": "SMO", "isVUS": "true", "variantName": "R703P"}, {"geneName": "SOCS1", "isVUS": "true", "variantName": "L150Q"}, {"geneName": "SOX2", "isVUS": "true", "variantName": "A30S"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "S2185F"}, {"geneName": "SUZ12", "isVUS": "true", "variantName": "S53L"}, {"geneName": "TAF1", "isVUS": "true", "variantName": "R123T"}, {"geneName": "TNFAIP3", "isVUS": "true", "variantName": "E451Q"}, {"geneName": "TSHR", "isVUS": "true", "variantName": "G235R"}, {"geneName": "WDR90", "isVUS": "true", "variantName": "R690Q"}, {"geneName": "ZNF217", "isVUS": "true", "variantName": "P823L"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "ERBB3", "Include": "true", "Alterations": {"Alteration": {"Name": "V104L", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "V104L"}}, "Interpretation": "ERBB3 (also known as HER3) encodes a member of the epidermal growth factor receptor (EGFR) family (Sheng et al., 2011; 21364581). ERBB3 mutations such as observed here have been shown to be activating (Jaiswal et al., 2013; 23680147, Li et al., 2014; 24997986, Collier et al., 2013; 23843458, Mishra et al., 2018; 29963236). ERBB3 mutations have been reported with highest incidence in cancers of the meninges (31%), urinary tract (11%), stomach (7.5%), skin (7.2%), endometrium (6.8%), prostate (5.3%), large intestine (5.2%), biliary tract (4.7%), and cervix (4%) and at lower frequencies in other tumor types (COSMIC, Apr 2022)(Tate et al., 2019; 30371878). High expression of ERBB3 mRNA or ERBB3 protein has been found in a number of tumor types, including those of the breast, lung, ovary, stomach, colon, and bladder (Gunes et al., 2013; 23333248, Bellezza et al., 2013; 24013863, Skrzypski et al., 2013; 23870818, M\u00fcller_Tidow et al., 2005; 15753374, Yoon et al., 2013; 24151090, Peng et al., 2008; 18000824, Wei et al., 2007; 17671674, Paterson et al., 2013; 22733579, Leng et al., 1997; 11324501, Tanner et al., 2006; 16896008, L\u00e9del et al., 2014; 24300455). Elevated ERBB3 expression has been associated with increased disease severity or negative prognostic indicators in glioblastoma (Song et al., 2018; 29888103), gastric cancer (Begnami et al., 2011; 21709195, Hayashi et al., 2008; 19047113), non_small cell lung cancer (M\u00fcller_Tidow et al., 2005; 15753374), and colorectal cancer (Baiocchi et al., 2009; 19390858). ERBB3 amplification in breast cancer has been correlated with reduced disease_free survival, although some studies have found no association with prognosis (Sassen et al., 2008; 18182100, Witton et al., 2003; 12845624, Koutras et al., 2008; 18985033, Pawlowski et al., 2000; 11106235, Travis et al., 1996; 8688326, Quinn et al., 1994; 7821892, Gasparini et al., 1994; 7908213, Lemoine et al., 1992; 1333787). The data associating ERBB3 expression and invasion and metastasis in urothelial carcinoma were similarly conflicting (Rajkumar et al., 1996; 8869284, Junttila et al., 2003; 14614020, Rotterud et al., 2005; 15892828, Tsai et al., 2005; 16360440, Chow et al., 1997; 9230911, Chow et al., 2001; 11448910). ERBB3 cooperates with other ERBB family members, in particular ERBB2, for efficient signaling (Black et al., 2019; 31351986, Baselga and Swain, 2009; 19536107, Jaiswal et al., 2013; 23680147, Jura et al., 2009; 20007378). Therefore, ERBB3 amplification or activating mutation may predict sensitivity to therapies targeting ERBB2, including antibodies such as trastuzumab, pertuzumab, and ado_trastuzumab emtansine (T_DM1), and dual EGFR/HER2 TKIs such as lapatinib and afatinib. Preclinical studies support the sensitivity of cells with ERBB3 activating mutations to various anti_ERBB2 agents (Jaiswal et al., 2013; 23680147, Umelo et al., 2016; 26689995, Mishra et al., 2018; 29963236). In a Phase 2 study of afatinib in platinum_refractory urothelial cancer, 2 patients with activating ERBB3 mutations but no EGFR or HER2 activating alterations experienced clinical benefit and PFS > 6 months (Choudhury et al., 2016; 27044931). Other studies in solid tumors have reported mixed efficacy for afatinib for patients with uncharacterized ERBB3 mutations (Verlingue et al., 2018; 29413684, Goss et al., 2018; 29902295). Case studies report clinical benefit from lapatinib combined with either capecitabine (Verlingue et al., 2018; 29413684) or trastuzumab (Bidard et al., 2015; 25953157, Verlingue et al., 2018; 29413684) for patients with breast cancer harboring activating ERBB3 mutations. However, Phase 2 trials have suggested limited efficacy of other ERBB2_targeting TKIs against ERBB3 mutations, with no objective response to neratinib in any of 16 patients with ERBB3_mutated solid tumors (Hyman et al., 2018; 29420467) or dacomitinib in either of 2 patients with ERBB3_mutated cutaneous squamous cell carcinoma (Cavalieri et al., 2018; 29734047).", "Include": "true", "ClinicalTrialNote": "Clinical and preclinical data support sensitivity of ERBB3 activating mutations to HER2_targeting TKIs, including afatinib and lapatinib. ERBB3 amplification or activating mutations may confer sensitivity to therapies targeting ERBB3.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": {"nctId": "NCT03810872", "Include": "true"}}}}, "ReferenceLinks": null}, {"Name": "MET", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "MET encodes a receptor tyrosine kinase, also known as c_MET or hepatocyte growth factor receptor (HGFR), that is activated by the ligand HGF; MET activation results in signaling mediated partly by the RAS_RAF_MAPK and PI3K pathways to promote proliferation (Appleman, 2011; 22042966, Jung et al., 2012; 22553051). MET has been reported to be amplified in cancer (Gao et al., 2013; 23550210), with amplification positively correlating with protein expression in some cancer types (Ang et al., 2013; 23898085, Abou_Bakr and Elbasmi, 2013; 23996864, Ho et al., 2013; 24258573, Dziadziuszko et al., 2012; 22237262, Madoz_G\u00farpide et al., 2015; 26319934) and associating with therapeutic response to MET inhibitors in a variety of cancer types (Kwak et al., 2015; ASCO GI Abstract 01, Ou et al., 2011; 21623265, Schwab et al., 2014; 24192513, Lennerz et al., 2011; 22042947, Chi et al., 2012; 22162573, Palma et al., 2014; 25232318, Le et al., 2015; 25922291, Ali et al., 2015; 25882375, Kwak et al., 2015; 26432108). In the TCGA datasets, amplification of MET has been found in several tumor types, with the highest incidences in ovarian serous cystadenocarcinoma (5.5%), esophageal carcinoma (3.4%), stomach adenocarcinoma (3.7%), and lung adenocarinoma (3.0%) datasets; lower incidences were observed in various other tumor types (cBioPortal, Sep 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Overexpression of MET mRNA and protein has been observed in a number of cancers (Ang et al., 2013; 23898085, Abou_Bakr and Elbasmi, 2013; 23996864, Ho et al., 2013; 24258573). MET amplification has been associated with poor prognosis in gastroesophageal adenocarcinoma, gastric and esophageal cancer (Miller et al., 2006; 16186806, Tuynman et al., 2008; 18349821, Anderson et al., 2006; 17062664, Lennerz et al., 2011; 22042947, Graziano et al., 2011; 22042954, Lee et al., 2011; 21424128, Lee et al., 2012; 22644302). Increased MET expression has been associated with poor prognosis in cutaneous malignant melanoma (Cruz et al., 2003; 12837985), gallbladder adenocarcinoma (Yang et al., 2012; 22172411), lung large cell neuroendocrine carcinoma (Rossi et al., 2005; 16314638), and breast cancer (Camp et al., 1999; 10590366, Lengyel et al., 2005; 15455388, Ghoussoub et al., 1998; 9554529). The prognostic value of MET amplification or expression in non_small cell lung cancer (NSCLC) (Yang et al., 2013; 23079155, Dziadziuszko et al., 2012; 22237262, Cappuzzo et al., 2009; 19255323, Park et al., 2012; 22207554, Chen et al., 2011; 22052229, Kanteti et al., 2009; 19817696, To et al., 2002; 11795945, Tsuta et al., 2012; 22198430), endometrial carcinoma (Felix et al., 2012; 22617129, Wagatsuma et al., 1998; 9452270, Bishop et al., 2011; 21168200, Felix et al., 2010; 20527227) or colon cancer (Garouniatis et al., 2013; 22733437, Liu et al., 2012; 22495710, Resnick et al., 2004; 15131045) have yielded conflicting results, although concurrent MET amplification and EGFR mutation have been correlated with reduced disease_free survival in NSCLC (Tanaka et al., 2012; 21733594). On the basis of extensive clinical evidence, MET amplification or activating mutations may predict sensitivity to MET_targeting therapies such as kinase inhibitors crizotinib, capmatinib, tepotinib, and cabozantinib. Crizotinib has benefited patients with MET_amplified non_small cell lung cancer (NSCLC) of varied histologies (Vassal et al., 2015; ASCO Abstract 2595, Li et al., 2015; ASCO Abstract 8090, Ou et al., 2011; 21623265, Schwab et al., 2014; 24192513, Le et al., 2015; 25922291, Schrock et al., 2017; 28315738), gastroesophageal cancer (Lennerz et al., 2011; 22042947), glioblastoma (Chi et al., 2012; 22162573), and carcinoma of unknown primary (Palma et al., 2014; 25232318). Capmatinib has demonstrated clinical efficacy for patients with MET_amplified NSCLC both as a monotherapy (Schuler et al., 2016; ASCO Abstract 9067, Wu et al., 2018; WCLC Abstract P1.01_97) and in combination with an EGFR_TKI for patients with concurrent activating EGFR mutations (Wu et al., 2018; 30156984, Gainor et al., 2020; 31864558, Gautschi et al., 2020; 31864554). Tepotinib has demonstrated efficacy for patients with MET_amplified hepatocellular carcinoma (Faivre et al., 2021; ASCO GI Abstract 329) and NSCLC (Le et al., 2021; ASCO Abstract 9021) as a monotherapy, as well as in combination with gefitinib for patients with MET_amplified and EGFR_mutated NSCLC (Yang et al., 2019; AACR Abstract CT193, Park et al., 2019; ESMO Abstract 477O, Wu et al., 2019; IASLC Abstract MA09.09). Savolitinib elicited responses in patients with MET_amplified papillary renal cell carcinoma (Gan et al., 2019; 30952639) and gastric cancer either alone or in combination with docetaxel (Lee et al., 2019; 31315834, Kim et al., 2019; 30695737). AMG 337 elicited an ORR of 50% (5/10), including 1 CR, for patients with MET_amplified gastric, esophageal, or gastroesophageal junction cancer (Kwak et al., 2015; ASCO GI Abstract 01). Patients with MET_amplified NSCLC (Spigel et al., 2013; 24101053) or MET_amplified gastric cancer (Catenacci et al., 2011; 22389872) treated with the MET_targeting antibody onartuzumab (MetMAb) achieved clinical responses. In addition, high MET expression has been suggested to predict patient response to therapies such as the monoclonal HGF_targeting antibody rilotumumab, as well as the combination of ramucirumab and the monoclonal MET_targeting antibody emibetuzumab (Oliner et al., 2012; ASCO Abstract 4005, Harding et al., 2019; 31142504). A first_in_human Phase 1 trial of telisotuzumab vedotin (teliso_V), a MET antibody_drug conjugate, reported activity in a subset of patients with MET_positive NSCLC, with an ORR of 19% (3/16) and a DCR of 56% (9/16); no responses were observed in any other patients (Strickler et al., 2019; 30285518). A subsequent Phase 2 trial of teliso_V in patients with MET_positive NSCLC reported a 35% (13/37) ORR in patients with non_squamous, EGFR_wildtype tumors, which met the prespecified criteria for transition to the next stage; lower ORRs were observed in patients with squamous (14%; 3/21) or non_squamous EGFR_mutated (13%; 4/30) tumors (Camidge et al., 2021; AACR Abstract CT179).", "Include": "true", "ClinicalTrialNote": "Activating MET alterations may confer sensitivity to MET inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Capmatinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Capmatinib is a selective MET tyrosine kinase inhibitor that is FDA approved to treat patients with non_small cell lung cancer harboring MET exon 14 skipping_associated alterations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data in non_small cell lung cancer (Schuler et al., 2016; ASCO Abstract 9067, Wu et al., 2018; WLCL Abstract P1.01_97, Yang et al., 2019; AACR Abstract CT193, Park et al., 2019; ESMO Abstract 477O, Wu et al., 2019; IASLC Abstract MA09.09, Le et al., 2021; ASCO Abstract 9021), hepatocellular carcinoma (Faivre et al., 2021; ASCO GI Abstract 329), renal cell carcinoma (Gan et al., 2019; 30952639), and gastric cancer (Lee et al., 2019; 31315834), MET amplification may predict sensitivity to selective MET inhibitors. </p> <p><b>Supporting Data:</b> Capmatinib has been investigated primarily for the treatment of NSCLC, demonstrating efficacy as monotherapy for patients with MET amplification (Wolf et al., 2020; ASCO Abstract 9509, Schuler et al., 2020; 32240796, Wu et al., 2018; WCLC Abstract P1.01_97) or MET exon 14 skipping alterations (Wolf et al., 2020; 32877583, Schuler et al., 2020; 32240796) as well as in combination with EGFR inhibitors for patients with MET amplification (Wu et al. 2018; 30156984, Gainor et al., 2020; 31864558, Gautschi et al., 2020; 31864554). Multiple Phase 1 and 2 clinical studies have reported limited efficacy for capmatinib monotherapy in non_NSCLC indications, with no responses observed for patients with MET_amplified glioblastoma (n=10)(Van den Bent et al., 2020; 31776899), MET_overexpressing gastric cancer (n=9)(Bang et al., 2020; 31778267), or other advanced solid tumors with MET amplification or overexpression (n=11)(Bang et al., 2020; 31778267, Esaki et al., 2019; 30724423). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Crizotinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Crizotinib is an inhibitor of the kinases MET, ALK, ROS1, and RON. It is FDA approved to treat patients with ALK rearrangement_ or ROS1 rearrangement_positive non_small cell lung cancer (NSCLC), and to treat pediatric and young adult patients with ALK rearrangement_positive anaplastic large cell lymphoma (ALCL). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Sensitivity of MET alterations to crizotinib is suggested by extensive clinical data in patients with MET_amplified cancers, including non_small cell lung cancer (NSCLC) (Vassal et al., 2015; ASCO Abstract 2595, Li et al., 2015; ASCO Abstract 8090)(Ou et al., 2011; 21623265, Schwab et al., 2014; 24192513, Le et al., 2015; 25922291), gastric cancer (Ali et al., 2015; 25882375), gastroesophageal cancer (Lennerz et al., 2011; 22042947), glioblastoma (Chi et al., 2012; 22162573), and carcinoma of unknown primary (Palma et al., 2014; 25232318), as well as in patients with MET_mutated cancers, including NSCLC (Frampton et al., 2015; 25971938, Paik et al., 2015; 25971939, Benderra et al., 2016; 26845121, Waqar et al., 2015; 25898962, Mendenhall and Goldman, 2015; 25898965, Jenkins et al., 2015; 25769807), renal cell carcinoma (RCC) (Stein et al., 2015; 25457019), and histiocytic sarcoma (Frampton et al., 2015; 25971938). Crizotinib has also benefited patients with NSCLC or histiocytic sarcoma tumors harboring various alterations associated with MET exon 14 skipping (Awad et al., 2017; ASCO Abstract 8511, Frampton et al., 2015; 25971938, Paik et al., 2015; 25971939, Waqar et al., 2015; 25898962, Mendenhall and Goldman, 2015; 25898965, Jenkins et al., 2015; 25769807). </p> <p><b>Supporting Data:</b> Crizotinib has demonstrated efficacy in patients with NSCLC and ALK rearrangements (Shaw et al., 2016; ASCO Abstract 9066, Lu et al., 2016; ASCO Abstract 9058, Yoshida et al., 2016; 27354483, Solomon et al., 2014; 25470694, Shaw et al., 2013; 23724913), ROS1 rearrangements (Moro_Sibilot et al., 2015; ASCO Abstract 8065, Goto et al., 2016; ASCO Abstract 9022, Shaw et al., 2014; 25264305, Mazieres et al., 2015; 25667280, Scheffler et al., 2015; 25868855), an NTRK1 fusion (Vaishnavi et al., 2013; 24162815), or MET activation (Drilon et al., 2016; ASCO Abstract 108, Vassal et al., 2015; ASCO Abstract 2595, Camidge et al., 2014; ASCO Abstract 8001, Li et al., 2015; ASCO Abstract 8090, Schrock et al., 2016; 27343443, Jorge et al., 2015; 26791794, Paik et al., 2015; 25971939, Mahjoubi et al., 2016; 26892698, Benderra et al., 2016; 26845121, Waqar et al., 2015; 25898962, Mendenhall and Goldman, 2015; 25898965, Jenkins et al., 2015; 25769807, Awad et al., 2016; 26729443, Jorge et al., 2015; 26791794, Schwab et al., 2014; 24192513, Zhang et al., 2016; 26724472, Ou et al., 2011; 21623265, Le et al., 2015; 25922291). Crizotinib has also benefited patients with MET_mutated renal cell carcinoma (Diamond et al., 2013; 23610116) and patients with MET_amplified gastroesophageal cancer, glioblastoma, and carcinoma of unknown primary (Lennerz et al., 2011; 22042947, Shi et al., 2012; 22162573, Palma et al., 2014; 25232318). While a Phase 1b study evaluating crizotinib for the treatment of patients with ALK_positive malignancies, reported ORR of 52.9% (9/17) and 66.7% (6/9) in patients with lymphoma and inflammatory myofibroblastic tumors (IMT), respectively, an ORR of 11.8% (2/17) was reported for patients with other types of tumors (Gambacorti_Passerini et al., 2017; ASH Abstract 4128). Whereas median PFS and median OS were not reached for patients with lymphoma or IMT, median PFS was 1.3 months and median OS was 8.3 months for patients with other tumor types, and the median duration of treatment was ~1 month relative to 1_3 years for patients with lymphoma or IMT (Gambacorti_Passerini et al., 2017; ASH Abstract 4128). A Phase 1 clinical trial of crizotinib in pediatric solid tumors reported objective responses in 14/79 patients, including nine CRs and five PRs; response was enriched in patients with activating alterations in ALK (Moss\u00e9 et al., 2013; 23598171). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Cabozantinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Cabozantinib inhibits multiple tyrosine kinases, including MET, RET, VEGFRs, and ROS1. It is FDA approved as monotherapy to treat patients with renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), medullary thyroid cancer (MTC), and differentiated thyroid cancer (DTC). It is also approved in combination with nivolumab to treat RCC. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Sensitivity of MET alterations to cabozantinib is suggested by clinical responses in patients with non_small cell lung cancer (NSCLC) harboring MET mutations associated with MET exon 14 skipping, with or without concurrent MET amplification (Paik et al., 2015; 25971939, Klempner et al., 2016; 27693535), as well as by extensive preclinical data (Yakes et al., 2011; 21926191, Weber et al., 2014; 25260782, Navis et al., 2013; 23484006, Yeh et al., 2015; 26013381, Lee et al., 2014; 25534569, Torres et al., 2011; 21540237, Sameni et al., 2015; 26432786). </p> <p><b>Supporting Data:</b> A randomized Phase 2 discontinuation study of cabozantinib in 9 solid tumor types reported ORRs of 0% to 22% and response durations of 3.3 to 11.2 months across cohorts with ORRs of 10% or greater observed for patients with ovarian cancer (22% [15/69, 1 CR]), metastatic breast cancer (14% [6/44]), and non_small cell lung cancer (NSCLC) (10% [6/60]) (Sch\u00f6ffski et al., 2017; 29059635, Hellerstedt et al., 2019; 30528315). A Phase 1 study of cabozantinib for advanced solid tumors reported a 17% (4/23) ORR in the dose escalation cohort and an ORR of 20% (4/20) and a DCR of 100% (20/20) in the expansion cohort for Japanese patients with NSCLC (Nokihara et al., 2019; 30718102). In the context of studies for specific solid tumors, the randomized Phase 3 EXAM study for patients with advanced medullary thyroid cancer reported an association of cabozantinib with improved PFS compared with placebo (11.2 vs. 4.0 months, HR=0.28) and a higher ORR (28% vs. 0%), with PFS improvement observed regardless of RET mutation status (Elisei et al., 2013; 24002501). The randomized Phase 3 CELESTIAL study for patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib reported significantly longer OS (10.2 vs. 8.0 months, HR=0.76) and PFS (5.2 vs. 1.9 months, HR=0.44) as well as an increased ORR (3.8% vs. 0.4%) with cabozantinib when compared to placebo (Abou_Alfa et al., 2018; 29972759). The Phase 2 CABOSUN trial of first line cabozantinib versus sunitinib for patients with intermediate_ or poor_risk advanced clear cell renal cell carcinoma demonstrated significantly improved median PFS (8.2 vs. 5.6 months, HR=0.66), prolonged median OS (30.3 vs. 21.8 months), and higher ORR (33% [26/79] vs. 12% [9/78]) with cabozantinib compared with sunitinib (Choueiri et al., 2017; 28199818). The Phase 2 CABONE study of cabozantinib reported ORRs of 26% (10/39) for patients with advanced Ewing sarcoma and 12% (5/42) for patients with advanced osteosarcoma (Italiano et al., 2020; 32078813). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Tepotinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Tepotinib is a selective MET tyrosine kinase inhibitor that is FDA approved to treat patients with non_small cell lung cancer harboring MET exon 14 skipping alterations. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data in non_small cell lung cancer (Schuler et al., 2016; ASCO Abstract 9067, Wu et al., 2018; WLCL Abstract P1.01_97, Yang et al., 2019; AACR Abstract CT193, Park et al., 2019; ESMO Abstract 477O, Wu et al., 2019; IASLC Abstract MA09.09, Le et al., 2021; ASCO Abstract 9021), hepatocellular carcinoma (Faivre et al., 2021; ASCO GI Abstract 329), renal cell carcinoma (Gan et al., 2019; 30952639), and gastric cancer (Lee et al., 2019; 31315834), MET amplification may predict sensitivity to selective MET inhibitors. </p> <p><b>Supporting Data:</b> Tepotinib has primarily been investigated in non_small cell lung cancer and has demonstrated efficacy as a single agent for patients with MET amplification (Le et al., 2021; ASCO Abstract 9021) and MET exon 14_skipping alterations (Paik et al., 2020; 32469185, Mazieres et al., 2020; ESMO Abstract 1283P). Tepotinib has also been shown to be efficacious in combination with gefitinib for patients with concurrent EGFR mutation and MET amplification or MET overexpression in Phase 2 studies (Wu et al., 2019; IASLC Abstract MA09.09, Park et al., 2019; ESMO Abstract 477O). In advanced hepatocellular carcinoma, Phase 2 studies of tepotinib reported improved ORR and PFS for both treatment_naive and previously treated patients with MET protein overexpression (Ryoo et al., 2018; ESMO Abstract 186P, Ryoo et al., 2018; ESMO Abstract 621PD, Decaens et al., 2019; ESMO Abstract 698P, Faivre et al., 2021; ASCO GI Abstract 329). In a Phase 1 study of advanced solid tumors, tepotinib monotherapy yielded an ORR of 1.3% and a DCR of 24%, with 2 confirmed PRs observed for patients with esophageal or lung cancer and 2 unconfirmed PRs for patients with colorectal or nasopharyngeal cancer (Falchook et al., 2020; 31822497). In another Phase 1 study of solid tumors, tepotinib yielded a DCR of 17% (2/12), with 2 SD of \u226512 weeks observed in a patient with gastric cancer and another with urachal cancer (Shitara et al., 2020; 32328660). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03175224", "Include": "true"}, {"nctId": "NCT04647838", "Include": "true"}, {"nctId": "NCT03297606", "Include": "true"}, {"nctId": "NCT04116541", "Include": "true"}, {"nctId": "NCT04887194", "Include": "true"}, {"nctId": "NCT04693468", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "63", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "63"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level that may be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors in multiple solid tumor types (Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915). High or elevated TMB has been most frequently reported in melanoma (17_42%) (Johnson et al., 2016; 27671167, Snyder et al., 2014; 25409260, Van Allen et al., 2015; 26359337), colorectal cancer (CRC; 8_25%) (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103)(Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117), endometrial carcinoma (7_24%) (Frampton et al., 2016; ASCO Abstract 11558, Santin et al., 2016; ASCO Abstract 414)(Cancer Genome Atlas Research Network., 2013; 23636398), intestinal_type stomach adenocarcinoma (20%) (Frampton et al., 2016; ASCO Abstract 11558), and non_small cell lung carcinoma (NSCLC; 8_13%) (Spigel et al., 2016; ASCO Abstract 9017, Jiang et al., 2016; ASCO Abstract e23128). In patients with NSCLC, increased TMB is associated with higher tumor grade and poor prognosis (Xiao et al., 2016; 27009843), as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high_TMB samples each), but not BRAF (10.3%) or KRAS (9.4%) (Spigel et al., 2016; ASCO Abstract 9017). Although some studies have reported a lack of association between smoking and increased TMB in NSCLC (Schwartz et al., 2016; ASCO Abstract 8533, Xiao et al., 2016; 27009843, Shim et al., 2015; 26200269), several other large studies did find a strong link (Govindan et al., 2012; 22980976, Ding et al., 2008; 18948947, Imielinski et al., 2012; 22980975, Kim et al., 2014; 24323028). In CRC, elevated TMB is associated with a higher frequency of BRAF V600E driver mutations (Cancer Genome Atlas Network, 2012; 22810696, Stadler et al., 2016; 27022117) and with microsatellite instability (MSI) (George et al., 2016; ASCO Abstract 3587, Nagahashi et al., 2016; ASCO Abstract e15103, Stadler et al., 2016; 27022117), which in turn has been reported to correlate with better prognosis (Samowitz et al., 2001; 11535541, Elsaleh and Iacopetta, 2001; 12445368, Brueckl et al., 2003; 12820457, Guidoboni et al., 2001; 11438476, Gryfe et al., 2000; 10631274, Sinicrope et al., 2006; 16952542, Guastadisegni et al., 2010; 20627535, Laghi and Malesci, 2012; 22722556). Although increased TMB is associated with increased tumor grade in endometrioid endometrial carcinoma (Mehnert et al., 2016; 27159395, Cancer Genome Atlas Research Network., 2013; 23636398, Hussein et al., 2015; 25394778, Church et al., 2013; 23528559) and bladder cancer (Cazier et al., 2016; 24777035), it is also linked with improved prognosis in patients with these tumor types (Rosenberg et al., 2016; ASCO Abstract 104, Cancer Genome Atlas Research Network., 2013; 23636398). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors (Samstein et al., 2019; 30643254). Analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy, compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB \u226510 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials (Marabelle et al., 2020; 32919526, Cristescu et al., 2018; 30309915). Together, these studies suggest that patients with TMB \u226510 Muts/Mb may derive clinical benefit from PD_1 or PD_L1 inhibitors.", "Include": "true", "ClinicalTrialNote": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Cemiplimab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Cemiplimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved to treat patients with NSCLC with high PD_L1 expression (TPS \u2265 50%), cutaneous squamous cell carcinoma (CSCC), or basal cell carcinoma (BCC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Cemiplimab has been studied primarily in advanced cutaneous squamous cell carcinoma (CSCC), where it elicited a combined ORR of 48% (41/85) in Phase 1 and 2 studies (Migden et al., 2018; 29863979). A Phase 2 trial of cemiplimab in patients with basal cell carcinoma (BCC) reported ORRs of 31% (5 CRs and 21 PRs) in patients with locally advanced BCC and 21% (6 PRs) in patients with metastatic BCC (Stratigos et al., 2020; EMSO Abstract LBA47, Lewis et al. 2020; doi: 10.1136/jitc_2020_SITC2020.0428). The Phase 3 EMPOWER_Lung 1 trial for advanced non_small cell lung cancer (NSCLC) with PD_L1 expression \u226550% reported that cemiplimab is associated with improved PFS (8.2 vs. 5.7 months), OS (not reached vs. 14.2 months), and ORR (37% vs. 21%) compared with chemotherapy (Sezer et al., 2020; ESMO Abstract LBA52). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Dostarlimab", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Dostarlimab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer or solid tumors. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Dostarlimab has been studied primarily in recurrent and advanced mismatch repair_deficient (dMMR) endometrial and non_endometrial cancers (Andre et al., 2021; ASCO GI Abstract 9, Oaknin et al., 2020; 33001143, Berton et al., 2021; ASCO Abstract 2564). In the Phase 1 GARNET trial, single_agent dostarlimab elicited an ORR of 39% (41/106) and an immune_related ORR of 46% (50/110) for patients with non_endometrial dMMR solid tumors (Andre et al., 2021; ASCO GI Abstract 9, Andre et al., 2021; ESMO GI Abstract SO_9). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Nivolumab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response. It is FDA approved as a monotherapy in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, colorectal cancer (CRC), classical Hodgkin lymphoma (cHL), gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma or squamous cell carcinoma (ESCC). It is also approved in combination with cabozantinib to treat RCC, and in combination with relatlimab to treat melanoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Nivolumab monotherapy has been reported to elicit clinical benefit for patients with multiple types of solid tumors, including melanoma (27_31% ORR) (Postow et al., 2015; 25891304, Larkin et al., 2015; 26027431, Robert et al., 2014; 25399552, Topalian et al., 2014; 24590637, Weber et al., 2015; 25795410), non_small cell lung cancer (NSCLC; 17_20% ORR and 9_10 months median OS [mOS] for unselected patients) (Brahmer et al., 2014; ASCO Abstract 8112, Gettinger et al., 2014; ASCO Abstract 8024, Antonia et al., 2014; ASCO Abstract 8023, Rizvi et al., 2014; ASCO Abstract 8022, Antonia et al., 2014; ASCO Abstract 8113, Brahmer et al., 2015; 26028407, Borghaei et al., 2015; 26412456), urothelial carcinoma (20_26% ORR for unselected patients) (Sharma et al., 2019; 31100038, Sharma et al., 2017; 28131785), renal cell carcinoma (RCC; 26% ORR) (Amin et al., 2014; ASCO Abstract 5010, McDermott et al., 2016, ASCO Abstract 4507) (Motzer et al., 2014; 25452452, Topalian et al., 2012; 22658127, Brahmer et al., 2010; 20516446, Motzer et al., 2015; 26406148), microsatellite instability_high (MSI_High) colorectal cancer (CRC; 58% ORR) (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO GI Abstract 481), head and neck squamous cell carcinoma (11_17% ORR) (Gillison et al., 2016; AACR Abstract CT099, Ferris et al., 2016; ASCO Abstract 6009, Ferris et al. 2019; 31239321), ovarian cancer (6_15% ORR) (Brahmer et al., 2012; 22658128, Hamanishi et al., 2015; 26351349, Normann et al., 2019; 31074244), small cell lung cancer (SCLC; 10_12% ORR) (Calvo et al., 2015; ECC Abstract 3098, Hellmann et al., 2017; ASCO Abstract 8503, Antonia et al., 2016; 27269741), gastroesophageal carcinoma (12_18% ORR) (Le et al., 2016; ASCO GI Cancers Abstract 06, Kojima et al., 2016; ASCO GI Cancers Abstract TPS175, Janjigian et al., 2018; 30110194), and cancer of unknown primary (CUP; 22% ORR for unselected, previously treated patients) (Tanizaki et al., 2021; 34843940), as well as with Hodgkin lymphoma (66_87% ORR) (Ansell et al., 2015; ASH Abstract 583, Ansell et al., 2015; 25482239, Younes et al., 2016; 27451390). Combination treatment with nivolumab plus the CTLA_4 inhibitor ipilimumab has achieved further efficacy in melanoma (up to 61% ORR; mOS >60 months for the combination vs. 37 months for nivolumab monotherapy) (Hodi et al., 2018; 30361170, Postow et al., 2015; 25891304, Hodi et al., 2016; 27622997, Larkin et al., 2019; 31562797), NSCLC (mOS of 17 months) (Hellmann et al., 2019; 31562796), MSI_High CRC (64% ORR) (Lenz et al., 2020; ASCO GI Abstract 11), RCC (42% ORR) (Motzer et al., 2019; 31427204, Motzer et al., 2018; 29562145), SCLC (19_25% ORR) (Hellmann et al., 2017; ASCO Abstract 8503, Antonia et al., 2016; 27269741), urothelial carcinoma (38% ORR for unselected patients; 58% ORR for patients with \u22651% tumor PD_L1 expression) (Sharma et al., 2019; 31100038), and other solid tumors. Combinations of nivolumab with various targeted therapies, such as pazopanib (1 PR for a patient with epithelioid sarcoma) (Paoluzzi et al., 2016; ASCO Abstract 11047), sunitinib (9% ORR for unselected patients with sarcoma) (Broto et al., 2019; ESMO Abstract 1669O), cabozantinib (29% ORR for patients with immunotherapy_refractory urothelial carcinoma) (Nadal et al., 2018; ASCO Abstract 4528), or vemurafenib (1 durable PR for a patient with BRAF_V600E_mutated and PD_L1_positive anaplastic thyroid cancer) (Kollipara et al., 2017; 28778959), have also shown evidence of efficacy and continue to undergo clinical investigation. </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Atezolizumab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Atezolizumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC) and urothelial carcinoma, depending on treatment setting. Atezolizumab is also approved in combination with other therapies to treat patients with non_squamous NSCLC lacking EGFR or ALK alterations, small cell lung cancer, hepatocellular carcinoma, and BRAF V600_positive melanoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In the prospective Phase 2a MyPathway basket study evaluating atezolizumab for patients with TMB_High solid tumors, patients with TMB \u226516 Muts/Mb achieved improved ORR (38% [16/42] vs. 2.1% [1/48]), DCR (62% [26/42] vs. 23% [11/48]), mPFS (5.7 vs. 1.8 months, HR 0.34), and mOS (19.8 vs. 11.4, HR 0.53) as compared to those with TMB \u226510 and <16 Muts/Mb (Friedman et al., 2022; 34876409). In a retrospective analysis of patients with 17 solid tumor types (comprised of 47% NSCLC, 40% urothelial carcinoma, and 13% encompassing 15 other solid tumors), TMB of 16 Muts/Mb or greater was reported to be associated with an improved ORR to atezolizumab compared to chemotherapy (30% vs. 14%)(Legrand et al., 2018; ASCO Abstract 12000). Atezolizumab has been studied primarily for the treatment of non_small cell lung cancer (NSCLC) (Smith et al., 2016; ASCO Abstract 9028, Mazieres et al., 2016; ASCO Abstract 9032, Besse et al., 2015; ECC Abstract 16LBA, Spigel et al., 2015; ASCO Abstract 8028, Fehrenbacher et al., 2016; 26970723, Herbst et al., 2014; 25428504) and urothelial carcinoma (Balar et al., 2016; ASCO Abstract LBA4500, Dreicer et al., 2016; ASCO Abstract 4515)(Rosenberg et al., 2016; 26952546, Powles et al., 2014; 25428503). A study of atezolizumab as monotherapy for patients with advanced solid tumors reported a median PFS of 18 weeks and an ORR of 21%, including confirmed responses in 25.6% (11/43) of melanomas, 12.5% (7/56) of renal cell carcinomas (RCC) and 16.7% (1/6) of colorectal cancers (CRCs)(Herbst et al., 2014; 25428504). As single_agent therapy in genomically unselected young patients (<30 years old) with relapsed or refractory cancers, atezolizumab elicited an ORR of 1.5% (1/67) for patients with solid tumors, with similar safety and pharmacokinetics as seen in adults (Geoerger et al., 2020; 31780255). A Phase 1a study of atezolizumab reported an ORR of 14.5% (9/62), a median PFS of 5.6 months, and a median OS of 28.9 months for patients with clear cell RCC (McDermott et al., 2016; 26755520). A Phase 1b study evaluated atezolizumab combined with nab_paclitaxel for patients with previously treated metastatic triple_negative breast cancer (mTNBC) and reported confirmed objective responses for 41.7% (10/24) of patients; no dose_limiting toxicities were observed (Adams et al., 2016; ASCO Abstract 1009). A Phase 1b study that evaluated atezolizumab in combination with the MEK inhibitor cobimetinib for advanced solid tumors reported an ORR of 8.3% (7/84) in patients with CRC, 40.9% (9/22) in patients with melanoma, 17.9% (5/28) in patients with NSCLC, and 18.8% (3/16) in patients with other tumors (ovarian cancer, clear_cell sarcoma, and RCC); there was no association between BRAF or KRAS mutation status and response rate in any disease setting, and no dose_limiting toxicities were encountered (Hellmann et al., 2019; 30918950, Bendell et al., 2016; ASCO Abstract 3502). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Avelumab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Avelumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 in order to enhance antitumor immune responses. It is FDA approved to treat patients 12 years and older with Merkel cell carcinoma, or for urothelial carcinoma in various treatment settings. The combination of avelumab and axitinib is FDA approved for patients with renal cell carcinoma (RCC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> The JAVELIN Phase 1b study has demonstrated clinical benefit from single_agent avelumab in a variety of solid tumor types, including non_small cell lung carcinoma (NSCLC)(Verschraegen et al., 2016; ASCO Abstract 9036), gastric carcinoma and gastroesophageal junction (GEJ) adenocarcinoma (Chung et al., 2016; ASCO Abstract 4009), urothelial carcinoma (Patel et al., 2016; ESMO Abstract 777PD), mesothelioma (Hassan et al., 2016; ASCO Abstract 8503), ovarian carcinoma (Disis et al., 2016; ASCO Abstract 5533), and breast cancer (Dirix et al., 2016; SABCS Abstract S1_04), and from avelumab combined with axitinib in renal cell carcinoma (Larkin et al., 2016; ESMO Abstract 775PD). Emerging clinical data show a positive trend toward the association of tumor cell PD_L1 expression and improved ORR, PFS, or OS in NSCLC in the first_line setting and in ovarian and breast cancer (Disis et al., 2016; ASCO Abstract 5533, Dirix et al., 2016; SABCS Abstract S1_04, Verschraegen et al., 2016; ASCO Abstract 9036). Limited clinical data indicate activity of avelumab in adrenocortical carcinoma, metastatic castration_resistant prostate cancer, and thymic cancer (Le Tourneau et al., 2016; ASCO Abstract 4516, Fakhrejahani et al., 2017; ASCO GU Abstract 159, Rajan et al., 2016; ASCO Abstract e20106). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Nivolumab + Ipilimumab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Nivolumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with PD_L1 and PD_L2, reducing inhibition of the antitumor immune response, and ipilimumab is a cytotoxic T_lymphocyte antigen 4 (CTLA_4)_blocking antibody. The combination is FDA approved in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non_small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and pleural mesothelioma. Furthermore, nivolumab is approved in combination with ipilimumab to treat patients with mismatch repair_deficient (dMMR) or microsatellite instability_high (MSI_H) colorectal cancer (CRC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hodi et al., 2019; AACR abstract CT037), a TMB score of \u226510 Muts/Mb (as measured by this assay) may predict sensitivity to combination nivolumab and ipilimumab treatment. </p> <p><b>Supporting Data:</b> Combination treatment with nivolumab plus the CTLA_4 inhibitor ipilimumab has achieved efficacy in melanoma (up to 61% ORR; mOS >60 months for the combination vs. 37 months for nivolumab monotherapy) (Hodi et al., 2018; 30361170, Postow et al., 2015; 25891304, Hodi et al., 2016; 27622997, Larkin et al., 2019; 31562797), NSCLC (17 months mOS) (Hellmann et al., 2019; 31562796), MSI_High CRC (64% ORR) (Lenz et al., 2020; ASCO GI Abstract 11), RCC (42% ORR) (Motzer et al., 2019; 31427204, Motzer et al., 2018; 29562145), SCLC (19\u201325% ORR) (Hellmann et al., 2017; ASCO Abstract 8503, Antonia et al., 2016; 27269741), urothelial carcinoma (38% ORR in unselected patients; 58% ORR in patients with \u22651% tumor PD_L1 expression) (Sharma et al., 2019; 31100038), and other solid tumors. </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Pembrolizumab", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Pembrolizumab is a monoclonal antibody that binds to the PD_1 receptor and blocks its interaction with the ligands PD_L1 and PD_L2 to enhance antitumor immune responses. It is FDA approved for patients with tumor mutational burden (TMB)_high (\u226510 Muts/Mb), microsatellite instability_high (MSI_H), or mismatch repair_deficient (dMMR) solid tumors; as monotherapy for PD_L1_positive non_small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), cervical cancer, or esophageal cancer; and in combination with chemotherapy for PD_L1_positive triple_negative breast cancer (TNBC) or cervical cancer. It is also approved in various treatment settings as monotherapy for patients with melanoma, HNSCC, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma, endometrial carcinoma that is MSI_H or dMMR, classical Hodgkin lymphoma, or primary mediastinal large B_cell lymphoma; and in combination with chemotherapy or targeted therapy for NSCLC, HNSCC, esophageal or gastroesophageal junction cancer, renal cell carcinoma, TNBC, or endometrial carcinoma that is not MSI_H or dMMR. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> In the Phase 2 KEYNOTE 158 multi_solid tumor trial, treatment with the PD_1 inhibitor pembrolizumab led to improved ORR for patients with TMB of 10 Muts/Mb or higher compared those with TMB <10 Muts/Mb (28.3% [34/120] vs. 6.5% [41/635])(Marabelle et al., 2020; 32919526). In the KEYNOTE 028/012 pan_solid tumor trials, a similar improvement in ORR was reported for patients with >103 non_synonymous mutations/exome (~ equivalency >8 Muts/Mb as measured by this assay) compared to those with <103 non_synonymous mutations/exome (30.6% [11/36] vs. 6.5% [5/77])(Cristescu et al., 2018; 30309915). Pembrolizumab has achieved significant clinical benefit for patients with PD_L1_expressing solid tumors including gastric carcinoma (ORR=22.0%)(Muro et al., 2016; 27157491), esophageal carcinoma (ORR=22.0%)(Doi et al., 2015; ASCO Abstract 4010), endometrial carcinoma (ORR=13.0%)(Ott et al., 2016; ASCO Abstract 5581, Mehnert et al., 2016; 27159395), lung carcinoma (median OS=14.9 months)(Herbst et al., 2015; 26712084), urothelial tract carcinoma (ORR=24.0%)(Pilmack et al., 2014; ESMO Abstract LBA23), head and neck carcinoma (ORR=12.0\u201326.0%)(Chow et al., 2014; ESMO Abstract LBA31, Hsu et al., 2015; ESMO Abstract 2801, Cohen et al., 2016; ASCO Abstract 6017, Seiwert et al., 2016; 27247226), breast carcinoma (ORR=16.0_25.0%)(Nanda et al., 2014; SABCS Abstract S1_09, Nanda et al., 2016; 27138582), cervical squamous cell carcinoma (ORR=12.5%)(Frenel et al., 2016; ASCO Abstract 5515), thyroid carcinoma (ORR=9.0%)(Mehnert et al., 2016; ASCO Abstract 6091), and pleural mesothelioma (ORR=24.0%)(Alley et al., 2015; AACR Abstract CT103). In the KEYNOTE_051 Phase 1/2 study of pembrolizumab for the treatment of pediatric patients with advanced cancer, PRs were reported in 8 patients including 2 adrenocortical carcinomas, 2 mesotheliomas, 1 malignant ganglioglioma, 1 epithelioid sarcoma, 1 lymphoepithelial carcinoma, and 1 malignant rhabdoid (Geoerger et al., 2020; 31812554). Clinical studies have reported responses to pembrolizumab in combination with other immunotherapies such as ipilimumab in recurrent advanced non_small cell lung carcinoma (NSCLC)(ORR=24.0%) (Patnaik et al., 2015; ASCO Abstract 8011, Gubens et al., 2016; ASCO Abstract 9027), and nivolumab in glioma (2/12 PRs, 4/12 SDs)(Schaff et al., 2015; SNO Abstract IMCT_18). Clinical benefit has also been achieved with pembrolizumab in combination with chemotherapy for advanced non_squamous NSCLC (Papadimitrakopoulou et al., 2015; ASCO Abstract 8031), IDO_1 inhibitor epacadostat for solid tumors (Gangadhar et al., 2015; SITC Abstract 511), HDAC inhibitor entinostat for breast and endometrial cancer (Tolcher et al., 2018; AACR Abstract CT179), bevacizumab for glioblastoma (Reardon et al., 2016; ASCO Abstract 2010), and lenvatinib for patients with advanced endometrial carcinoma that is not MSI_H or dMMR (Makker et al., 2019; 30922731). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Durvalumab", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Durvalumab is a monoclonal antibody that binds to PD_L1 and blocks its interaction with PD_1 to enhance antitumor immune responses. It is FDA approved to treat patients with non_small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical data across solid tumors (Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915), TMB of \u226510 Muts/Mb (based on this assay or others) may predict sensitivity to immune checkpoint inhibitors targeting PD_1 or PD_L1. An association between higher TMB and improved OS, median PFS, and ORR has been observed in large pan_solid tumor studies for patients treated with immune checkpoint inhibitors (Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386). </p> <p><b>Supporting Data:</b> Single_agent durvalumab has demonstrated efficacy in non_small cell lung cancer (Bais et al., 2017; AACR Abstract 3720/5, Garassino et al., 2016; IASLC Abstract PLO4a.03), and head and neck squamous cell carcinoma (Segal et al., 2016; ESMO Abstract 949O, Segal et al., 2015; ASCO Abstract 3011). In patients with advanced solid tumors, durvalumab monotherapy has elicited disease control rates (DCRs) of 36.8\u201346.2% (7/19 to 12/26) in Phase 1/2 studies (Lutzky et al., 2014; ASCO Abstract 3001, Iguchi et al., 2015; ASCO Abstract 3039). Durvalumab is also under investigation in combination with other agents in Phase 1/2 trials. In advanced melanoma, durvalumab in combination with trametinib and dabrafenib elicited ORRs and DCRs of 76.2% (16/21) and 100% (21/21) in patients with BRAF_mutant tumors, and durvalumab with trametinib elicited ORRs and DCRs of 21.4% (3/14) and 64.3% (9/14) in patients whose tumors were BRAF wild_type (Ribas et al., 2015; ASCO Abstract 3003). Durvalumab in combination with the PARP inhibitor olaparib has shown activity in patients with metastatic castration_resistant prostate cancer and progression on enzalutamide and/or abiraterone (Karzai et al., 2017; ASCO Genitourinary Abstract 162) and in patients with BRCA_wild_type breast or gynecological cancer (Lee et al., 2016; ASCO Abstract 3015). Durvalumab in combination with the anti_CTLA4 antibody tremelimumab, but not durvalumab as a single_agent, has shown activity in patients with previously treated advanced germ cell tumors (Necchi et al., 2019; 30243800). Responses have also been reported for patients with solid tumors treated with durvalumab in combination with the anti_PD_1 antibody MEDI0680 (Hamid et al., 2016; ESMO Abstract 1050PD), the CXCR2 antagonist AZD5069 (Hong et al., 2016; ESMO 2016 Abstract 1049PD), or the ATR inhibitor AZD6738 (Yap et al., 2016; EORTC_NCI_AACR Abstract 1LBA). In patients with treatment_refractory solid tumors, concurrent durvalumab and radiotherapy achieved an ORR of 60% (6/10) for in_field evaluable lesions, including 2 CRs and 4 PRs (Levy et al., 2016; 27764686). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04237649", "Include": "true"}, {"nctId": "NCT04589845", "Include": "true"}, {"nctId": "NCT04521621", "Include": "true"}, {"nctId": "NCT04261439", "Include": "true"}, {"nctId": "NCT03799003", "Include": "true"}, {"nctId": "NCT03861793", "Include": "true"}, {"nctId": "NCT04047862", "Include": "true"}, {"nctId": "NCT03530397", "Include": "true"}, {"nctId": "NCT03396445", "Include": "true"}, {"nctId": "NCT04892498", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "ETV6", "Include": "true", "Alterations": {"Alteration": {"Name": "inversion intron 5, rearrangement intron 5", "AlterationProperties": {"AlterationProperty": [{"isEquivocal": "false", "name": "inversion intron 5"}, {"isEquivocal": "false", "name": "rearrangement intron 5"}]}, "Interpretation": "ETV6 encodes an ETS family transcription factor required for hematopoiesis. The portion of chromosome 12 that encodes ETV6 is frequently involved in translocation events, and at least 30 fusion partners have been identified to date (Kralik et al., 2011; 21401966, De Braekeleer et al., 2012; 22578774). ETV6 rearrangements have been implicated in various hematopoietic malignancies (Wlodarska et al., 1996; 9031109) and have been reported to be pathogenic by a number of different mechanisms including activation of a partner oncogene, ETV6 inactivation, or aberrant transcription factor activity (De Braekeleer et al., 2012; 22578774). Alterations such as seen here may disrupt ETV6 function or expression (Montpetit and Sinnett, 2001; 11423994, Donaldson et al., 1996; 8598195, Green et al., 2010; 20400516, Tognon et al., 2004; 15143160, Kim et al., 2001; 11483520). ETV6 mutation has been observed in up to 7% of cutaneous squamous cell carcinomas (cBio_Li et al., 2015; 25589618), 6% of colorectal adenocarcinomas (cBio_Seshagiri et al., 2012; 22895193), 5.5% of bladder cancers (cBio_Kim et al., 2015; 25092538), 4% each of melanomas and endometrial carcinomas, and in lower frequencies in other tumor types cBioPortal, Apr 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). High ETV6 expression associated with poor prognosis in one study (Ke et al., 2017; 28831010), and low ETV6 expression associated with improved OS and disease_free survival in patients with NSCLC (Liang et al., 2015; 26045802). There are no approved therapies that address ETV6 mutation or inactivation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FLT4", "Include": "true", "Alterations": {"Alteration": {"Name": "V160L", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "V160L"}}, "Interpretation": "FLT4 encodes the protein fms_related tyrosine kinase 4, also known as VEGFR_3 (vascular endothelial growth factor receptor 3). Targeting of VEGF receptors has been a major therapeutic strategy in cancer as growth of new blood and lymph vessels is a critical determinant of tumor growth and metastasis (Koch et al., 2011; 21711246, Werynska et al., 2009; 20164015). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. In the TCGA datasets, FLT4 mutation has been reported in 11.6% of cutaneous melanomas, 7.5% of endometrial carcinomas, 5.6% of colorectal adenocarcinomas, 5.5% of stomach adenocarcinomas, and at lower incidence across a range of other tumor types (cBioPortal, Apr 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of FLT4 alterations in solid tumors are generally limited (PubMed, Apr 2022). Based on clinical studies, FLT4 amplification may be associated with sensitivity to kinase inhibitors with activity against VEGFR3 such as axitinib and sorafenib; responses to axitinib have been observed in patients with FLT4_amplified differentiated thyroid carcinoma (Schechter et al., 2015; 25641339), and responses to sorafenib have been reported in patients with FLT4_amplified angiosarcoma (Guo et al., 2011; 20949568, D Angelo et al., 2012; ASCO Abstract 10019). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "HIST1H1D", "Include": "true", "Alterations": {"Alteration": {"Name": "Q182*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Q182*"}}, "Interpretation": "HIST1H1D encodes histone H1.3 (H1D), a linker histone that interacts with DNA between nucleosomes and functions in the regulation of gene expression and compaction of chromatin into higher order structures (Sancho et al., 2008; 18927631, Soshnev et al., 2021; 34580064). Missense mutations in linker histones affecting the globular and C_terminal domains have been identified in cancer and often correlate with loss of function (Soshnev et al., 2021; 34580064), whereas other alterations are mostly uncharacterized. Recurrent missense mutations in the genes that encode H1 isoforms B\u2013E, have been reported at high frequencies in B cell lymphomas, including 30\u201340% of diffuse large B cell lymphomas (DLBCLs), 30% of follicular lymphomas and 50% of Hodgkin lymphomas, and lower frequencies across other tumor types (Yusufova et al., 2020; 33299181, Krysiak et al., 2017; 28064239, Okosun et al., 2014; 24362818, Li et al., 2014; 24435047, Lohr et al., 2012; 22343534). Published data investigating the prognostic implications of HIST1H1D alterations in cancer are limited (PubMed, Apr 2022). There are currently no therapies available to directly address genomic alterations in HISTH1D.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "KEAP1", "Include": "true", "Alterations": {"Alteration": {"Name": "E41*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E41*"}}, "Interpretation": "KEAP1 encodes a substrate adaptor protein that regulates the cellular response to oxidative stress by providing substrate specificity for a CUL3_dependent ubiquitin ligase (Lo and Hannink, 2006; 17046835). KEAP1 exerts anti_tumor effects through negative regulation of NRF2, a transcription factor encoded by NFE2L2 (Wakabayashi et al., 2003; 14517554, Kansanen et al., 2013; 24024136, Hast et al., 2013; 23382044); KEAP1 inactivation promotes cancer progression through NRF2_mediated chemoresistance and cell growth (Kansanen et al., 2013; 24024136, Hast et al., 2013; 23382044). Somatic mutation of KEAP1 occurs in a range of solid tumors, including gastric, hepatocellular, colorectal, and lung cancers (Yoo et al., 2012; 22348534). KEAP1 mutations are rare in hematological malignancies, occurring in fewer than 1% of samples analyzed (COSMIC, 2022)(Tate et al., 2019; 30371878). In a retrospective analysis of the pan_solid MSKCC dataset, KEAP1 mutation correlated with reduced OS (13.28 vs. 26.53 months) (Xu et al., 2020; 32272498). A study of patients with localized non_small cell lung cancer (NSCLC) identified pathogenic KEAP1 and NFE2L2 mutations as predictors of local recurrence following radiotherapy but not surgery; limited preclinical data also showed that treatment with a glutaminase inhibitor sensitized KEAP1_mutated NSCLC cells to radiation (Binkley et al., 2020; 33071215). In other preclinical studies, treatment with AKT inhibitors sensitized lung cancer cells harboring KEAP1 or NFE2L2 mutations to both chemotherapy and radiation therapy (Chowdhry et al., 2013; 22964642, Abazeed et al., 2013; 23980093). Mixed clinical data have been reported for the association between KEAP1 mutations and the response to immunotherapy. A pan_cancer study of immunotherapy showed that patients with KEAP1 mutations had shorter OS (10 vs. 20 months) than those without (Chen et al., 2020; 32175433). However, another study across solid tumors showed that KEAP1 mutations were associated with higher tumor mutational burden (TMB) and PD_L1 expression, as well as improved survival outcomes with immunotherapy compared with other treatments (20.0 vs. 11.5 months) (Xu et al., 2020; 32272498). For patients with non_small cell lung cancer (NSCLC), a study of PD_L1 inhibitors showed that patients with concurrent mutations of STK11 and KEAP1 (n=39) experienced significantly shorter PFS (1.6 vs. 2.5 months, HR=1.5) and OS (4 vs. 11 months, HR=1.9) compared with patients with STK11_ and KEAP1_wildtype tumors (n=210) despite significantly higher TMB in the group harboring STK11 and KEAP1 mutations (median 9.4 vs. 6.1 Muts/Mb) (Arbour et al., 2018; IASLC WCLC Abstract MA19.09). Retrospective analyses of patients with NSCLC who received immunotherapy reported reduced OS (p=0.040) for patients harboring KEAP1_ or NFE2L2_mutated tumors (Zhang et al., 2020; 32471565) or STK11_ or KEAP1_mutated tumors (p <0.001) (Shang et al., 2020; WCLC Abstract P75.02) compared with those without. Studies of immune checkpoint inhibitors for patients with lung adenocarcinoma showed that coexisting mutations between KEAP1, PBRM1, SMARCA4, STK11, and KRAS were associated with worse OS (Marinelli et al., 2020; 32866624, Ricciuti et al., 2020; WCLC Abstract P14.26). An exploratory analysis of a subset of patients with PD_L1_positive NSCLC treated in the first_line setting with pembrolizumab showed similar ORR, PFS, and OS when comparing patients with STK11 or KEAP1 mutations and those without (Cho et al., 2020; AACR Abstract CT084). In addition, preclinical data suggest that KEAP1 inactivation increases tumor demand for glutamine and increases tumor sensitivity to glutaminase inhibitors like telaglenastat (Gwinn et al., 2018; 29316436, Sayin et al., 2017; 28967864, Romero et al., 2017; 28967920). Limited clinical data suggest that KEAP1 mutations may predict improved clinical benefit from combinations of glutaminase inhibitors and anti_PD_1 inhibitors (Skoulidis et al., 2021; ASCO Abstract TPS9627); a Phase 1/2 study of the glutaminase inhibitor telaglenastat (CB_839) plus nivolumab to treat advanced NSCLC reported better clinical benefit rates and median PFS for patients with KEAP1 mutations (75% [3/4] vs. 15% [2/13], 6.4 vs. 3.7 months), KRAS mutations (38% [3/8] vs. 20% [2/10], 4.5 vs. 3.7 months), or KEAP1 and KRAS concurrent mutations (100% [2/2] vs. 13% [1/8], 7.2 vs. 3.7 months) compared with patients without these mutations (Skoulidis et al., 2021; ASCO Abstract TPS9627). The KEAP1 mutation has also been identified as a potential biomarker for sensitivity to combined AKT and TXNRD1 inhibition in lung cancer (Dai et al., 2013; 23824739).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_high (MSI_H) has been observed at high frequency in endometrial cancers (14_33%)(Santin et al., ASCO 2016; Abstract 414, Zighelboim et al., 2007; 17513808, Hampel et al., 2006; 16885385, Stelloo et al., 2016; 27006490, Kanopiene et al., 2014; 25458958, Black et al., 2006; 16549821, Nout et al., 2012; 22609107, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452), colorectal cancers (CRCs; 10_15%)(Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894), and gastric cancers (12_35%)(Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086) and at lower frequencies in many other tumor types, including esophageal (Hall et al., 2016; ASCO Gastrointestinal Cancer Symposium Abstract 528, Farris et al., 2011; 21422910), small bowel (Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06, Agaramet al., 2010; 20395525, Ruemmele et al., 2009; 19252434, Planck et al., 2003; 12627520, Hibi et al., 1995; 7775257, Muneyuki et al., 2000; 11117578), hepatobiliary (Zhang et al., 2005; 15918185, Chiappini et al., 2004; 14656944, Suto et al., 2001; 11223838, Momoi et al., 2001; 11580146, Liengswangwong et al., 2003; 14506736, Moy et al., 2015; 25680569, Yoshida et al., 2000; 11063221), prostate (Cheng et al., 2016; Genitourinary Cancers Symposium Abstract 251, Pritchard et al., 2014; 25255306, Azzouzi et al., 2007; 17233803, Burger et al., 2006; 16924473), and urinary tract carcinomas (Harper et al., 2015; USCAP Abstract 905, Bai et al., 2013; 23690119, Giedl et al., 2014; 25319978, Yamamoto et al., 2006; 16675567). In one study, MSI_H status was associated with a positive prognostic effect in patients with gastric cancer treated with surgery alone and a negative predictive effect in patients treated with chemotherapy (Smyth et al., 2015; ASCO Gastrointestinal Cancers Symposium Abstract 62). Data regarding the role of MSI_H on prognosis and survival in endometrial cancer are conflicting (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao_Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958, Black et al., 2006; 16549821). However, studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI_H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI_H predicts for poor prognosis in this subset of endometrial tumors. On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TET2", "Include": "true", "Alterations": {"Alteration": {"Name": "V1417F", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "V1417F"}}, "Interpretation": "TET2 encodes a tumor suppressor involved in reversing DNA methylation marks, a process critical for proper gene regulation (Ito et al., 2010; 20639862, Guo et al., 2011; 21496894). Although alterations such as seen here have not been fully characterized and are of unknown functional significance, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. TET2 alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Jan 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of TET2 alterations in solid tumors are limited (PubMed, Jan 2022). There are no targeted therapies available to address genomic alterations in TET2 in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "splice site 375G>T", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "splice site 375G>T"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). Pan_cancer analysis of the TCGA datasets across 12 cancer types identified TP53 as the most frequently mutated gene, with 42% of more than 3,000 tumors harboring a TP53 mutation; in this study TP53 mutation occurred most frequently in ovarian serous carcinoma (95%), lung squamous cell carcinoma (SCC) (79%), head and neck SCC (70%), colorectal adenocarcinoma (59%), lung adenocarcinoma (52%), and bladder urothelial carcinoma (50%) (Kandoth et al., 2013; 24132290). In one study of 55 patients with lung adenocarcinoma, TP53 alterations correlated with immunogenic features including PD_L1 expression, tumor mutation burden and neoantigen presentation; likely as a consequence of this association TP53 mutations correlated with improved clinical outcomes to PD_1 inhibitors pembrolizumab and nivolumab in this study (Dong et al., 2016; 28039262). TP53 mutation has not been consistently demonstrated to be a significant independent prognostic marker in the context of CRC (Russo et al., 2005; 16172461). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TRAF3", "Include": "true", "Alterations": {"Alteration": {"Name": "Q492*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Q492*"}}, "Interpretation": "TRAF3, a member of the TRAF family of adaptor proteins, has E3 ubiquitin ligase activity and is a critical determinant of B_cell survival (Xie et al., 2008; 18499506, Kayagaki et al., 2007; 17991829). TRAF3 loss leads to the activation of the NF_kB pathway and is thought to function as a tumor suppressor in a variety of B_cell lineage neoplasms (Keats et al., 2007; 17692805, Liao et al., 2004; 15084608, Annunziata et al., 2007; 17692804, Nagel et al., 2009; 19693093, Gardam et al., 2011; 21300983). Alterations such as seen here may disrupt TRAF3 function or expression. TRAF3 mutations have been reported with the highest incidences in the uterine corpus endometrial carcinoma (3.4%), skin cutaneous melanoma (2.7%), cervical squamous cell carcinoma (2.4%), stomach adenocarcinoma (2.3%), and colorectal adenocarcinoma (2.0%) TCGA datasets (cBioPortal, Mar 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of TRAF3 alterations in solid tumors are limited (PubMed, Mar 2022). There are no approved therapies that directly target TRAF3 inactivation or the activation of the NF_kB pathway, although these are under development. The Bruton\u2019s tyrosine kinase inhibitor ibrutinib has been reported to inhibit NF_kB pathway activation in chronic lymphocytic leukemia samples and myeloma cells (Herman et al., 2014; 24659631, Herman et al., 2011; 21422473; Rushworth et al., 2013; 22975686). However, preclinical data in mantle cell lymphoma cells suggest that inactivation of TRAF3 or the related TRAF2 may correlate with insensitivity to ibrutinib and to the PKC inhibitor sotrastaurin (Rahal et al., 2014; 24362935). This insensitivity was attributed to activation of alternative NF_kB signaling, which could be inhibited by targeting the kinase NIK (MAP3K14) in preclinical assays (Rahal et al., 2014; 24362935).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "ERBB3", "Alteration": "V104L", "Title": "An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2", "Locations": "Li\u00e8ge (Belgium), Brussels (Belgium), Gent (Belgium)", "NCTID": "NCT03810872", "Note": "Clinical and preclinical data support sensitivity of ERBB3 activating mutations to HER2_targeting TKIs, including afatinib and lapatinib. ERBB3 amplification or activating mutations may confer sensitivity to therapies targeting ERBB3.", "Include": "true"}, {"Gene": "MET", "Alteration": "amplification", "Title": "CBT_101 Study for Advanced Solid Tumors and c_Met Dysregulation", "StudyPhase": "PHASE 1/2", "Target": "MET", "Locations": "Taipei City (Taiwan), Taipei (Taiwan), New Taipei City (Taiwan), Taoyuan City (Taiwan), Tainan (Taiwan), Singapore (Singapore), Nedlands (Australia), Saransk (Russian Federation), North Adelaide (Australia), Bedford Park (Australia)", "NCTID": "NCT03175224", "Note": "Activating MET alterations may confer sensitivity to MET inhibitors.", "Include": "true"}, {"Gene": "MET", "Alteration": "amplification", "Title": "Tepotinib in Solid Tumors Harboring MET Alterations", "StudyPhase": "PHASE 2", "Target": "MET", "Locations": "Cheonan (Korea, Republic of), Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of)", "NCTID": "NCT04647838", "Note": "Activating MET alterations may confer sensitivity to MET inhibitors.", "Include": "true"}, {"Gene": "MET", "Alteration": "amplification", "Title": "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)", "StudyPhase": "PHASE 2", "Target": "VEGFRs, ABL, SRC, ALK, ROS1, AXL, TRKA, MET, TRKC, DDR2, KIT, EGFR, PD_1, CTLA_4, PARP, CDK4, CDK6, FLT3, CSF1R, RET, mTOR, ERBB2, MEK, BRAF, SMO", "Locations": "Vancouver (Canada), Edmonton (Canada), Saskatoon (Canada), Regina (Canada), Ottawa (Canada), Montreal (Canada), Toronto (Canada), Kingston (Canada), London (Canada)", "NCTID": "NCT03297606", "Note": "Activating MET alterations may confer sensitivity to MET inhibitors.", "Include": "true"}, {"Gene": "MET", "Alteration": "amplification", "Title": "A Study Evaluating the Activity of Anti_cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.", "StudyPhase": "PHASE 2", "Target": "CDK6, CDK4, MDM2, MET, ROS1, RET, VEGFRs", "Locations": "Nice (France), Lyon (France), Marseille (France), Toulouse (France), Bordeaux (France)", "NCTID": "NCT04116541", "Note": "Activating MET alterations may confer sensitivity to MET inhibitors.", "Include": "true"}, {"Gene": "MET", "Alteration": "amplification", "Title": "PK Study to Assess Drug_drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates", "StudyPhase": "PHASE 1", "Target": "AXL, KIT, DDR2, VEGFRs, PDGFRA, TRKA, MET, FLT3, RET, TRKB, PD_1", "Locations": "Texas, Virginia", "NCTID": "NCT04887194", "Note": "Activating MET alterations may confer sensitivity to MET inhibitors.", "Include": "true"}, {"Gene": "MET", "Alteration": "amplification", "Title": "Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial", "StudyPhase": "PHASE 1", "Target": "PARP, CDK4, CDK6, VEGFRs, ALK, ROS1, AXL, TRKA, MET, TRKC", "Locations": "Texas", "NCTID": "NCT04693468", "Note": "Activating MET alterations may confer sensitivity to MET inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "63", "Title": "KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "ADORA2A, CD73, PD_1", "Locations": "Taipei (Taiwan), Shatin, New Territories (Hong Kong), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Toronto (Canada), Missouri", "NCTID": "NCT04237649", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "63", "Title": "Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha", "Locations": "Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi an (China), Tianjin (China), Beijing (China), Chengdu City (China), Changchun (China)", "NCTID": "NCT04589845", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "63", "Title": "A Study of V937 in Combination With Pembrolizumab (MK_3475) in Participants With Advanced/Metastatic Solid Tumors (V937_013)", "StudyPhase": "PHASE 1/2", "Target": "PD_1", "Locations": "Taipei (Taiwan), Taoyuan (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Kashiwa (Japan), Afula (Israel), Jerusalem (Israel), Tel Aviv (Israel), Warszawa (Poland), Oslo (Norway)", "NCTID": "NCT04521621", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "63", "Title": "A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab", "StudyPhase": "PHASE 1", "Target": "PD_1", "Locations": "Taipei (Taiwan), Chuo ku (Japan), Essen (Germany), Napoli (Italy), Leuven (Belgium), Barcelona (Spain), California, Texas", "NCTID": "NCT04261439", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "63", "Title": "A Study of ASP1951 in Subjects With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_1, TNFRSF18", "Locations": "Taipei (Taiwan), Taichung (Taiwan), Daegu (Korea, Republic of), Chungcheongbukdo (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Washington, California, Utah", "NCTID": "NCT03799003", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "63", "Title": "A Dose Escalation and Cohort Expansion Study of Subcutaneously_Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti_PD_1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY_2)", "StudyPhase": "PHASE 1/2", "Target": "PD_1", "Locations": "Taipei (Taiwan), Tainan (Taiwan), Suwon (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Edmonton (Canada), Badalona (Spain), Rotterdam (Netherlands), Valencia (Spain), Madrid (Spain)", "NCTID": "NCT03861793", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "63", "Title": "Study of BGB_A1217 in Combination With Tislelizumab in Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_1, TIGIT", "Locations": "Taipei (Taiwan), Hualien City (Taiwan), Taichung (Taiwan), Fujian (China), Hangzhou (China), Shanghai (China), Guangdong (China), Changsha (China), Wuhan (China), Jinju_si (Korea, Republic of)", "NCTID": "NCT04047862", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "63", "Title": "A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PD_L1, PD_1, CTLA_4", "Locations": "Taipei (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Cheongju_si (Korea, Republic of), Incheon (Korea, Republic of), Seoul (Korea, Republic of), Gyeonggi_do (Korea, Republic of), Amsterdam (Netherlands), Ravenna (Italy), Meldola (Italy)", "NCTID": "NCT03530397", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "63", "Title": "Safety and Pharmacokinetics Study of MK_5890 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Adults With Advanced Solid Tumors (MK_5890_001)", "StudyPhase": "PHASE 1", "Target": "PD_1, CD27", "Locations": "Taipei (Taiwan), Seoul (Korea, Republic of), Jerusalem (Israel), Ramat Gan (Israel), Be er Sheva (Israel), Amsterdam (Netherlands), Rotterdam (Netherlands), Barcelona (Spain), Madrid (Spain), Pozuelo de Alarcon (Spain)", "NCTID": "NCT03396445", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}, {"Gene": "Tumor Mutation Burden", "Alteration": "63", "Title": "Hypofractionated Radiotherapy Combined With PD_1 Inhibitor Sequential GM_CSF and IL_2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)", "StudyPhase": "PHASE 2", "Target": "PD_1", "Locations": "Hangzhou (China), Suzhou (China), Wuxi (China), Hefei (China), Xuzhou (China)", "NCTID": "NCT04892498", "Note": "Increased tumor mutational burden may predict response to anti_PD_1 (alone or in combination with anti_CTLA_4) or anti_PD_L1 immune checkpoint inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21401966", "FullCitation": "Kralik JM, et al. Diagn Pathol (2011) pmid: 21401966", "Include": "true"}, {"number": "1", "ReferenceId": "22578774", "FullCitation": "De Braekeleer E, et al. Leuk. Res. (2012) pmid: 22578774", "Include": "true"}, {"number": "2", "ReferenceId": "9031109", "FullCitation": "Wlodarska I, et al. Leuk. Lymphoma (1996) pmid: 9031109", "Include": "true"}, {"number": "3", "ReferenceId": "11423994", "FullCitation": "Montpetit A, et al. Oncogene (2001) pmid: 11423994", "Include": "true"}, {"number": "4", "ReferenceId": "8598195", "FullCitation": "Donaldson LW, et al. EMBO J. (1996) pmid: 8598195", "Include": "true"}, {"number": "5", "ReferenceId": "20400516", "FullCitation": "Green SM, et al. J. Biol. Chem. (2010) pmid: 20400516", "Include": "true"}, {"number": "6", "ReferenceId": "15143160", "FullCitation": "Tognon CE, et al. Mol. Cell. Biol. (2004) pmid: 15143160", "Include": "true"}, {"number": "7", "ReferenceId": "11483520", "FullCitation": "Kim CA, et al. EMBO J. (2001) pmid: 11483520", "Include": "true"}, {"number": "8", "ReferenceId": "25589618", "FullCitation": "Li YY, et al. Clin. Cancer Res. (2015) pmid: 25589618", "Include": "true"}, {"number": "9", "ReferenceId": "22895193", "FullCitation": "Seshagiri S, et al. Nature (2012) pmid: 22895193", "Include": "true"}, {"number": "10", "ReferenceId": "25092538", "FullCitation": "Kim PH, et al. Eur. Urol. (2015) pmid: 25092538", "Include": "true"}, {"number": "11", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "12", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "13", "ReferenceId": "28831010", "FullCitation": "Ke L, et al. Proc. Natl. Acad. Sci. U.S.A. (2017) pmid: 28831010", "Include": "true"}, {"number": "14", "ReferenceId": "26045802", "FullCitation": "Liang JZ, et al. Int J Clin Exp Pathol (2015) pmid: 26045802", "Include": "true"}, {"number": "15", "ReferenceId": "21364581", "FullCitation": "Sheng Q, et al. Br. J. Cancer (2011) pmid: 21364581", "Include": "true"}, {"number": "16", "ReferenceId": "23680147", "FullCitation": "Jaiswal BS, et al. Cancer Cell (2013) pmid: 23680147", "Include": "true"}, {"number": "17", "ReferenceId": "24997986", "FullCitation": "Li M, et al. Nat. Genet. (2014) pmid: 24997986", "Include": "true"}, {"number": "18", "ReferenceId": "23843458", "FullCitation": "Collier TS, et al. J. Biol. Chem. (2013) pmid: 23843458", "Include": "true"}, {"number": "19", "ReferenceId": "29963236", "FullCitation": "Mishra R, et al. Oncotarget (2018) pmid: 29963236", "Include": "true"}, {"number": "20", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "21", "ReferenceId": "23333248", "FullCitation": "Gunes S, et al. Pathol. Res. Pract. (2013) pmid: 23333248", "Include": "true"}, {"number": "22", "ReferenceId": "24013863", "FullCitation": "Bellezza G, et al. Virchows Arch. (2013) pmid: 24013863", "Include": "true"}, {"number": "23", "ReferenceId": "23870818", "FullCitation": "Skrzypski M, et al. Clin Lung Cancer (2013) pmid: 23870818", "Include": "true"}, {"number": "24", "ReferenceId": "15753374", "FullCitation": "M\u00fcller_Tidow C, et al. Cancer Res. (2005) pmid: 15753374", "Include": "true"}, {"number": "25", "ReferenceId": "24151090", "FullCitation": "Yoon HH, et al. Cancer (2014) pmid: 24151090", "Include": "true"}, {"number": "26", "ReferenceId": "18000824", "FullCitation": "Peng D, et al. Int. J. Cancer (2008) pmid: 18000824", "Include": "true"}, {"number": "27", "ReferenceId": "17671674", "FullCitation": "Wei Q, et al. Int. J. Oncol. (2007) pmid: 17671674", "Include": "true"}, {"number": "28", "ReferenceId": "22733579", "FullCitation": "Paterson AL, et al. J. Pathol. (2013) pmid: 22733579", "Include": "true"}, {"number": "29", "ReferenceId": "11324501", "FullCitation": "Leng J, et al. Chin. Med. Sci. J. (1997) pmid: 11324501", "Include": "true"}, {"number": "30", "ReferenceId": "16896008", "FullCitation": "Tanner B, et al. J. Clin. Oncol. (2006) pmid: 16896008", "Include": "true"}, {"number": "31", "ReferenceId": "24300455", "FullCitation": "L\u00e9del F, et al. Eur. J. Cancer (2014) pmid: 24300455", "Include": "true"}, {"number": "32", "ReferenceId": "29888103", "FullCitation": "Song K, et al. Am J Cancer Res (2018) pmid: 29888103", "Include": "true"}, {"number": "33", "ReferenceId": "21709195", "FullCitation": "Begnami MD, et al. J. Clin. Oncol. (2011) pmid: 21709195", "Include": "true"}, {"number": "34", "ReferenceId": "19047113", "FullCitation": "Hayashi M, et al. Clin. Cancer Res. (2008) pmid: 19047113", "Include": "true"}, {"number": "35", "ReferenceId": "19390858", "FullCitation": "Baiocchi G, et al. Int J Colorectal Dis (2009) pmid: 19390858", "Include": "true"}, {"number": "36", "ReferenceId": "18182100", "FullCitation": "Sassen A, et al. Breast Cancer Res. (2008) pmid: 18182100", "Include": "true"}, {"number": "37", "ReferenceId": "12845624", "FullCitation": "Witton CJ, et al. J. Pathol. (2003) pmid: 12845624", "Include": "true"}, {"number": "38", "ReferenceId": "18985033", "FullCitation": "Koutras AK, et al. Br. J. Cancer (2008) pmid: 18985033", "Include": "true"}, {"number": "39", "ReferenceId": "11106235", "FullCitation": "Pawlowski V, et al. Clin. Cancer Res. (2000) pmid: 11106235", "Include": "true"}, {"number": "40", "ReferenceId": "8688326", "FullCitation": "Travis A, et al. Br. J. Cancer (1996) pmid: 8688326", "Include": "true"}, {"number": "41", "ReferenceId": "7821892", "FullCitation": "Quinn CM, et al. Histopathology (1994) pmid: 7821892", "Include": "true"}, {"number": "42", "ReferenceId": "7908213", "FullCitation": "Gasparini G, et al. Eur. J. Cancer (1994) pmid: 7908213", "Include": "true"}, {"number": "43", "ReferenceId": "1333787", "FullCitation": "Lemoine NR, et al. Br. J. Cancer (1992) pmid: 1333787", "Include": "true"}, {"number": "44", "ReferenceId": "8869284", "FullCitation": "Rajkumar T, et al. J. Pathol. (1996) pmid: 8869284", "Include": "true"}, {"number": "45", "ReferenceId": "14614020", "FullCitation": "Junttila TT, et al. Clin. Cancer Res. (2003) pmid: 14614020", "Include": "true"}, {"number": "46", "ReferenceId": "15892828", "FullCitation": "R\u00f8tterud R, et al. BJU Int. (2005) pmid: 15892828", "Include": "true"}, {"number": "47", "ReferenceId": "16360440", "FullCitation": "Tsai YS, et al. Urology (2005) pmid: 16360440", "Include": "true"}, {"number": "48", "ReferenceId": "9230911", "FullCitation": "Chow NH, et al. Virchows Arch. (1997) pmid: 9230911", "Include": "true"}, {"number": "49", "ReferenceId": "11448910", "FullCitation": "Chow NH, et al. Clin. Cancer Res. (2001) pmid: 11448910", "Include": "true"}, {"number": "50", "ReferenceId": "31351986", "FullCitation": "Black LE, et al. Am. J. Pathol. (2019) pmid: 31351986", "Include": "true"}, {"number": "51", "ReferenceId": "19536107", "FullCitation": "Baselga J, et al. Nat. Rev. Cancer (2009) pmid: 19536107", "Include": "true"}, {"number": "52", "ReferenceId": "20007378", "FullCitation": "Jura N, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 20007378", "Include": "true"}, {"number": "53", "ReferenceId": "26689995", "FullCitation": "Umelo I, et al. Oncotarget (2016) pmid: 26689995", "Include": "true"}, {"number": "54", "ReferenceId": "27044931", "FullCitation": "Choudhury NJ, et al. J. Clin. Oncol. (2016) pmid: 27044931", "Include": "true"}, {"number": "55", "ReferenceId": "29413684", "FullCitation": "Verlingue L, et al. Eur. J. Cancer (2018) pmid: 29413684", "Include": "true"}, {"number": "56", "ReferenceId": "29902295", "FullCitation": "Goss GD, et al. JAMA Oncol (2018) pmid: 29902295", "Include": "true"}, {"number": "57", "ReferenceId": "25953157", "FullCitation": "Bidard FC, et al. Ann. Oncol. (2015) pmid: 25953157", "Include": "true"}, {"number": "58", "ReferenceId": "29420467", "FullCitation": "Hyman DM, et al. Nature (2018) pmid: 29420467", "Include": "true"}, {"number": "59", "ReferenceId": "29734047", "FullCitation": "Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047", "Include": "true"}, {"number": "60", "ReferenceId": "22042966", "FullCitation": "J. Clin. Oncol. (2011) pmid: 22042966", "Include": "true"}, {"number": "61", "ReferenceId": "22553051", "FullCitation": "Jung KH, et al. Arch. Pharm. Res. (2012) pmid: 22553051", "Include": "true"}, {"number": "62", "ReferenceId": "23898085", "FullCitation": "Ang CS, et al. Anticancer Res. (2013) pmid: 23898085", "Include": "true"}, {"number": "63", "ReferenceId": "23996864", "FullCitation": "Abou_Bakr AA, et al. Gulf J Oncolog (2013) pmid: 23996864", "Include": "true"}, {"number": "64", "ReferenceId": "24258573", "FullCitation": "Ho JC, et al. Semin Respir Crit Care Med (2013) pmid: 24258573", "Include": "true"}, {"number": "65", "ReferenceId": "22237262", "FullCitation": "Dziadziuszko R, et al. J Thorac Oncol (2012) pmid: 22237262", "Include": "true"}, {"number": "66", "ReferenceId": "26319934", "FullCitation": "Madoz_G\u00farpide J, et al. J Transl Med (2015) pmid: 26319934", "Include": "true"}, {"number": "67", "ReferenceId": "21623265", "FullCitation": "Ou SH, et al. J Thorac Oncol (2011) pmid: 21623265", "Include": "true"}, {"number": "68", "ReferenceId": "24192513", "FullCitation": "Schwab R, et al. Lung Cancer (2014) pmid: 24192513", "Include": "true"}, {"number": "69", "ReferenceId": "22042947", "FullCitation": "Lennerz JK, et al. J. Clin. Oncol. (2011) pmid: 22042947", "Include": "true"}, {"number": "70", "ReferenceId": "22162573", "FullCitation": "Chi AS, et al. J. Clin. Oncol. (2012) pmid: 22162573", "Include": "true"}, {"number": "71", "ReferenceId": "25232318", "FullCitation": "Palma NA, et al. Case Rep Oncol (2014) pmid: 25232318", "Include": "true"}, {"number": "72", "ReferenceId": "25922291", "FullCitation": "Le X, et al. Clin Lung Cancer (2015) pmid: 25922291", "Include": "true"}, {"number": "73", "ReferenceId": "25882375", "FullCitation": "Ali SM, et al. Oncologist (2015) pmid: 25882375", "Include": "true"}, {"number": "74", "ReferenceId": "26432108", "FullCitation": "Kwak EL, et al. Cancer Discov (2015) pmid: 26432108", "Include": "true"}, {"number": "75", "ReferenceId": "16186806", "FullCitation": "Miller CT, et al. Oncogene (2006) pmid: 16186806", "Include": "true"}, {"number": "76", "ReferenceId": "18349821", "FullCitation": "Tuynman JB, et al. Br. J. Cancer (2008) pmid: 18349821", "Include": "true"}, {"number": "77", "ReferenceId": "17062664", "FullCitation": "Anderson MR, et al. Clin. Cancer Res. (2006) pmid: 17062664", "Include": "true"}, {"number": "78", "ReferenceId": "22042954", "FullCitation": "Graziano F, et al. J. Clin. Oncol. (2011) pmid: 22042954", "Include": "true"}, {"number": "79", "ReferenceId": "21424128", "FullCitation": "Lee J, et al. Oncol. Rep. (2011) pmid: 21424128", "Include": "true"}, {"number": "80", "ReferenceId": "22644302", "FullCitation": "Lee HE, et al. Br. J. Cancer (2012) pmid: 22644302", "Include": "true"}, {"number": "81", "ReferenceId": "12837985", "FullCitation": "Cruz J, et al. Oncology (2003) pmid: 12837985", "Include": "true"}, {"number": "82", "ReferenceId": "22172411", "FullCitation": "Yang L, et al. Hepatogastroenterology (2012) pmid: 22172411", "Include": "true"}, {"number": "83", "ReferenceId": "16314638", "FullCitation": "Rossi G, et al. J. Clin. Oncol. (2005) pmid: 16314638", "Include": "true"}, {"number": "84", "ReferenceId": "10590366", "FullCitation": "Camp RL, et al. Cancer (1999) pmid: 10590366", "Include": "true"}, {"number": "85", "ReferenceId": "15455388", "FullCitation": "Lengyel E, et al. Int. J. Cancer (2005) pmid: 15455388", "Include": "true"}, {"number": "86", "ReferenceId": "9554529", "FullCitation": "Ghoussoub RA, et al. Cancer (1998) pmid: 9554529", "Include": "true"}, {"number": "87", "ReferenceId": "23079155", "FullCitation": "Yang JJ, et al. Lung Cancer (2013) pmid: 23079155", "Include": "true"}, {"number": "88", "ReferenceId": "19255323", "FullCitation": "Cappuzzo F, et al. J. Clin. Oncol. (2009) pmid: 19255323", "Include": "true"}, {"number": "89", "ReferenceId": "22207554", "FullCitation": "Park S, et al. Histol. Histopathol. (2012) pmid: 22207554", "Include": "true"}, {"number": "90", "ReferenceId": "22052229", "FullCitation": "Chen YT, et al. J Thorac Oncol (2011) pmid: 22052229", "Include": "true"}, {"number": "91", "ReferenceId": "19817696", "FullCitation": "Kanteti R, et al. J. Environ. Pathol. Toxicol. Oncol. (2009) pmid: 19817696", "Include": "true"}, {"number": "92", "ReferenceId": "11795945", "FullCitation": "To C, et al. Exp. Cell Res. (2002) pmid: 11795945", "Include": "true"}, {"number": "93", "ReferenceId": "22198430", "FullCitation": "Tsuta K, et al. J Thorac Oncol (2012) pmid: 22198430", "Include": "true"}, {"number": "94", "ReferenceId": "22617129", "FullCitation": "Felix AS, et al. Br. J. Cancer (2012) pmid: 22617129", "Include": "true"}, {"number": "95", "ReferenceId": "9452270", "FullCitation": "Wagatsuma S, et al. Cancer (1998) pmid: 9452270", "Include": "true"}, {"number": "96", "ReferenceId": "21168200", "FullCitation": "Bishop EA, et al. Gynecol. Oncol. (2011) pmid: 21168200", "Include": "true"}, {"number": "97", "ReferenceId": "20527227", "FullCitation": "Felix AS, et al. Eur. J. Gynaecol. Oncol. (2010) pmid: 20527227", "Include": "true"}, {"number": "98", "ReferenceId": "22733437", "FullCitation": "Garouniatis A, et al. Int J Colorectal Dis (2013) pmid: 22733437", "Include": "true"}, {"number": "99", "ReferenceId": "22495710", "FullCitation": "Liu Y, et al. Tumori () pmid: 22495710", "Include": "true"}, {"number": "100", "ReferenceId": "15131045", "FullCitation": "Resnick MB, et al. Clin. Cancer Res. (2004) pmid: 15131045", "Include": "true"}, {"number": "101", "ReferenceId": "21733594", "FullCitation": "Tanaka A, et al. Lung Cancer (2012) pmid: 21733594", "Include": "true"}, {"number": "102", "ReferenceId": "28315738", "FullCitation": "Schrock AB, et al. J Thorac Oncol (2017) pmid: 28315738", "Include": "true"}, {"number": "103", "ReferenceId": "30156984", "FullCitation": "Wu YL, et al. J. Clin. Oncol. (2018) pmid: 30156984", "Include": "true"}, {"number": "104", "ReferenceId": "31864558", "FullCitation": "Gainor JF, et al. J Thorac Oncol (2020) pmid: 31864558", "Include": "true"}, {"number": "105", "ReferenceId": "31864554", "FullCitation": "Gautschi O, et al. J Thorac Oncol (2020) pmid: 31864554", "Include": "true"}, {"number": "106", "ReferenceId": "30952639", "FullCitation": "Gan HK, et al. Clin. Cancer Res. (2019) pmid: 30952639", "Include": "true"}, {"number": "107", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "108", "ReferenceId": "30695737", "FullCitation": "Kim ST, et al. Transl Oncol (2019) pmid: 30695737", "Include": "true"}, {"number": "109", "ReferenceId": "24101053", "FullCitation": "Spigel DR, et al. J. Clin. Oncol. (2013) pmid: 24101053", "Include": "true"}, {"number": "110", "ReferenceId": "22389872", "FullCitation": "Catenacci DV, et al. Cancer Discov (2011) pmid: 22389872", "Include": "true"}, {"number": "111", "ReferenceId": "31142504", "FullCitation": "Harding JJ, et al. Clin. Cancer Res. (2019) pmid: 31142504", "Include": "true"}, {"number": "112", "ReferenceId": "30285518", "FullCitation": "Strickler JH, et al. J. Clin. Oncol. (2018) pmid: 30285518", "Include": "true"}, {"number": "113", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "114", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "115", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "116", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "117", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "118", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "119", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "120", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "121", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "122", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "123", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "124", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "125", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "126", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "127", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "128", "ReferenceId": "27671167", "FullCitation": "Johnson DB, et al. Cancer Immunol Res (2016) pmid: 27671167", "Include": "true"}, {"number": "129", "ReferenceId": "25409260", "FullCitation": "Snyder A, et al. N. Engl. J. Med. (2014) pmid: 25409260", "Include": "true"}, {"number": "130", "ReferenceId": "26359337", "FullCitation": "Van Allen EM, et al. Science (2015) pmid: 26359337", "Include": "true"}, {"number": "131", "ReferenceId": "27022117", "FullCitation": "Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117", "Include": "true"}, {"number": "132", "ReferenceId": "27009843", "FullCitation": "Xiao D, et al. Oncotarget (2016) pmid: 27009843", "Include": "true"}, {"number": "133", "ReferenceId": "26200269", "FullCitation": "Shim HS, et al. J Thorac Oncol (2015) pmid: 26200269", "Include": "true"}, {"number": "134", "ReferenceId": "22980976", "FullCitation": "Govindan R, et al. Cell (2012) pmid: 22980976", "Include": "true"}, {"number": "135", "ReferenceId": "18948947", "FullCitation": "Ding L, et al. Nature (2008) pmid: 18948947", "Include": "true"}, {"number": "136", "ReferenceId": "22980975", "FullCitation": "Imielinski M, et al. Cell (2012) pmid: 22980975", "Include": "true"}, {"number": "137", "ReferenceId": "24323028", "FullCitation": "Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028", "Include": "true"}, {"number": "138", "ReferenceId": "11535541", "FullCitation": "Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541", "Include": "true"}, {"number": "139", "ReferenceId": "12445368", "FullCitation": "Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368", "Include": "true"}, {"number": "140", "ReferenceId": "12820457", "FullCitation": "Brueckl WM, et al. Anticancer Res. () pmid: 12820457", "Include": "true"}, {"number": "141", "ReferenceId": "11438476", "FullCitation": "Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476", "Include": "true"}, {"number": "142", "ReferenceId": "10631274", "FullCitation": "Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274", "Include": "true"}, {"number": "143", "ReferenceId": "16952542", "FullCitation": "Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542", "Include": "true"}, {"number": "144", "ReferenceId": "20627535", "FullCitation": "Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535", "Include": "true"}, {"number": "145", "ReferenceId": "22722556", "FullCitation": "Laghi L, et al. Dig Dis (2012) pmid: 22722556", "Include": "true"}, {"number": "146", "ReferenceId": "27159395", "FullCitation": "Mehnert JM, et al. J. Clin. Invest. (2016) pmid: 27159395", "Include": "true"}, {"number": "147", "ReferenceId": "25394778", "FullCitation": "Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778", "Include": "true"}, {"number": "148", "ReferenceId": "23528559", "FullCitation": "Church DN, et al. Hum. Mol. Genet. (2013) pmid: 23528559", "Include": "true"}, {"number": "149", "ReferenceId": "24777035", "FullCitation": "Cazier JB, et al. Nat Commun (2014) pmid: 24777035", "Include": "true"}, {"number": "150", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "151", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "152", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "153", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "154", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "155", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "156", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "157", "ReferenceId": "17046835", "FullCitation": "Lo SC, et al. J. Biol. Chem. (2006) pmid: 17046835", "Include": "true"}, {"number": "158", "ReferenceId": "14517554", "FullCitation": "Wakabayashi N, et al. Nat. Genet. (2003) pmid: 14517554", "Include": "true"}, {"number": "159", "ReferenceId": "24024136", "FullCitation": "Kansanen E, et al. Redox Biol (2013) pmid: 24024136", "Include": "true"}, {"number": "160", "ReferenceId": "23382044", "FullCitation": "Hast BE, et al. Cancer Res. (2013) pmid: 23382044", "Include": "true"}, {"number": "161", "ReferenceId": "22348534", "FullCitation": "Yoo NJ, et al. Histopathology (2012) pmid: 22348534", "Include": "true"}, {"number": "162", "ReferenceId": "32272498", "FullCitation": "Xu X, et al. Oncologist (2020) pmid: 32272498", "Include": "true"}, {"number": "163", "ReferenceId": "33071215", "FullCitation": "Binkley MS, et al. Cancer Discov (2020) pmid: 33071215", "Include": "true"}, {"number": "164", "ReferenceId": "22964642", "FullCitation": "Chowdhry S, et al. Oncogene (2013) pmid: 22964642", "Include": "true"}, {"number": "165", "ReferenceId": "23980093", "FullCitation": "Abazeed ME, et al. Cancer Res. (2013) pmid: 23980093", "Include": "true"}, {"number": "166", "ReferenceId": "32175433", "FullCitation": "Chen X, et al. Ann Transl Med (2020) pmid: 32175433", "Include": "true"}, {"number": "167", "ReferenceId": "32471565", "FullCitation": "Zhang C, et al. J Thorac Oncol (2020) pmid: 32471565", "Include": "true"}, {"number": "168", "ReferenceId": "32866624", "FullCitation": "Marinelli D, et al. Ann Oncol (2020) pmid: 32866624", "Include": "true"}, {"number": "169", "ReferenceId": "29316436", "FullCitation": "Gwinn DM, et al. Cancer Cell (2018) pmid: 29316436", "Include": "true"}, {"number": "170", "ReferenceId": "28967864", "FullCitation": "Sayin VI, et al. Elife (2017) pmid: 28967864", "Include": "true"}, {"number": "171", "ReferenceId": "28967920", "FullCitation": "Romero R, et al. Nat. Med. (2017) pmid: 28967920", "Include": "true"}, {"number": "172", "ReferenceId": "23824739", "FullCitation": "Dai B, et al. Cancer Res. (2013) pmid: 23824739", "Include": "true"}, {"number": "173", "ReferenceId": "18927631", "FullCitation": "Sancho M, et al. PLoS Genet. (2008) pmid: 18927631", "Include": "true"}, {"number": "174", "ReferenceId": "34580064", "FullCitation": "Soshnev AA, et al. Cancer Res (2021) pmid: 34580064", "Include": "true"}, {"number": "175", "ReferenceId": "33299181", "FullCitation": "Yusufova N, et al. Nature (2021) pmid: 33299181", "Include": "true"}, {"number": "176", "ReferenceId": "28064239", "FullCitation": "Krysiak K, et al. Blood (2017) pmid: 28064239", "Include": "true"}, {"number": "177", "ReferenceId": "24362818", "FullCitation": "Okosun J, et al. Nat. Genet. (2014) pmid: 24362818", "Include": "true"}, {"number": "178", "ReferenceId": "24435047", "FullCitation": "Li H, et al. Blood (2014) pmid: 24435047", "Include": "true"}, {"number": "179", "ReferenceId": "22343534", "FullCitation": "Lohr JG, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22343534", "Include": "true"}, {"number": "180", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "181", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "182", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "183", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "184", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "185", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "186", "ReferenceId": "17513808", "FullCitation": "Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808", "Include": "true"}, {"number": "187", "ReferenceId": "16885385", "FullCitation": "Hampel H, et al. Cancer Res. (2006) pmid: 16885385", "Include": "true"}, {"number": "188", "ReferenceId": "27006490", "FullCitation": "Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490", "Include": "true"}, {"number": "189", "ReferenceId": "25458958", "FullCitation": "Kanopien\u0117 D, et al. Medicina (Kaunas) (2014) pmid: 25458958", "Include": "true"}, {"number": "190", "ReferenceId": "16549821", "FullCitation": "Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821", "Include": "true"}, {"number": "191", "ReferenceId": "22609107", "FullCitation": "Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107", "Include": "true"}, {"number": "192", "ReferenceId": "21547578", "FullCitation": "Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578", "Include": "true"}, {"number": "193", "ReferenceId": "20005452", "FullCitation": "Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452", "Include": "true"}, {"number": "194", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "195", "ReferenceId": "15209621", "FullCitation": "Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621", "Include": "true"}, {"number": "196", "ReferenceId": "9537253", "FullCitation": "Wu MS, et al. Cancer Res. (1998) pmid: 9537253", "Include": "true"}, {"number": "197", "ReferenceId": "8536886", "FullCitation": "dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886", "Include": "true"}, {"number": "198", "ReferenceId": "23555086", "FullCitation": "Fang WL, et al. Biomed Res Int (2013) pmid: 23555086", "Include": "true"}, {"number": "199", "ReferenceId": "21422910", "FullCitation": "Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910", "Include": "true"}, {"number": "200", "ReferenceId": "20395525", "FullCitation": "Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525", "Include": "true"}, {"number": "201", "ReferenceId": "19252434", "FullCitation": "Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434", "Include": "true"}, {"number": "202", "ReferenceId": "12627520", "FullCitation": "Planck M, et al. Cancer (2003) pmid: 12627520", "Include": "true"}, {"number": "203", "ReferenceId": "7775257", "FullCitation": "Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257", "Include": "true"}, {"number": "204", "ReferenceId": "11117578", "FullCitation": "Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578", "Include": "true"}, {"number": "205", "ReferenceId": "15918185", "FullCitation": "Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185", "Include": "true"}, {"number": "206", "ReferenceId": "14656944", "FullCitation": "Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944", "Include": "true"}, {"number": "207", "ReferenceId": "11223838", "FullCitation": "Suto T, et al. J Surg Oncol (2001) pmid: 11223838", "Include": "true"}, {"number": "208", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "209", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "210", "ReferenceId": "25680569", "FullCitation": "Moy AP, et al. Virchows Arch. (2015) pmid: 25680569", "Include": "true"}, {"number": "211", "ReferenceId": "11063221", "FullCitation": "Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221", "Include": "true"}, {"number": "212", "ReferenceId": "25255306", "FullCitation": "Pritchard CC, et al. Nat Commun (2014) pmid: 25255306", "Include": "true"}, {"number": "213", "ReferenceId": "17233803", "FullCitation": "Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803", "Include": "true"}, {"number": "214", "ReferenceId": "16924473", "FullCitation": "Burger M, et al. J. Mol. Med. (2006) pmid: 16924473", "Include": "true"}, {"number": "215", "ReferenceId": "23690119", "FullCitation": "Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119", "Include": "true"}, {"number": "216", "ReferenceId": "25319978", "FullCitation": "Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978", "Include": "true"}, {"number": "217", "ReferenceId": "16675567", "FullCitation": "Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567", "Include": "true"}, {"number": "218", "ReferenceId": "25026289", "FullCitation": "Bilbao_Sieyro C, et al. Oncotarget (2014) pmid: 25026289", "Include": "true"}, {"number": "219", "ReferenceId": "20304627", "FullCitation": "Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627", "Include": "true"}, {"number": "220", "ReferenceId": "19275958", "FullCitation": "Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958", "Include": "true"}, {"number": "221", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "222", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "223", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "224", "ReferenceId": "21711246", "FullCitation": "Koch S, et al. Biochem. J. (2011) pmid: 21711246", "Include": "true"}, {"number": "225", "ReferenceId": "20164015", "FullCitation": "Wery\u0144ska B, et al. Folia Histochem. Cytobiol. (2009) pmid: 20164015", "Include": "true"}, {"number": "226", "ReferenceId": "25641339", "FullCitation": "Schechter RB, et al. Cancer Lett. (2015) pmid: 25641339", "Include": "true"}, {"number": "227", "ReferenceId": "20949568", "FullCitation": "Guo T, et al. Genes Chromosomes Cancer (2011) pmid: 20949568", "Include": "true"}, {"number": "228", "ReferenceId": "18499506", "FullCitation": "Xie P, et al. Cytokine Growth Factor Rev. () pmid: 18499506", "Include": "true"}, {"number": "229", "ReferenceId": "17991829", "FullCitation": "Kayagaki N, et al. Science (2007) pmid: 17991829", "Include": "true"}, {"number": "230", "ReferenceId": "17692805", "FullCitation": "Keats JJ, et al. Cancer Cell (2007) pmid: 17692805", "Include": "true"}, {"number": "231", "ReferenceId": "15084608", "FullCitation": "Liao G, et al. J. Biol. Chem. (2004) pmid: 15084608", "Include": "true"}, {"number": "232", "ReferenceId": "17692804", "FullCitation": "Annunziata CM, et al. Cancer Cell (2007) pmid: 17692804", "Include": "true"}, {"number": "233", "ReferenceId": "19693093", "FullCitation": "Nagel I, et al. Leukemia (2009) pmid: 19693093", "Include": "true"}, {"number": "234", "ReferenceId": "21300983", "FullCitation": "Gardam S, et al. Blood (2011) pmid: 21300983", "Include": "true"}, {"number": "235", "ReferenceId": "24659631", "FullCitation": "Herman SE, et al. Blood (2014) pmid: 24659631", "Include": "true"}, {"number": "236", "ReferenceId": "21422473", "FullCitation": "Herman SE, et al. Blood (2011) pmid: 21422473", "Include": "true"}, {"number": "237", "ReferenceId": "22975686", "FullCitation": "Rushworth SA, et al. Cell. Signal. (2013) pmid: 22975686", "Include": "true"}, {"number": "238", "ReferenceId": "24362935", "FullCitation": "Rahal R, et al. Nat. Med. (2014) pmid: 24362935", "Include": "true"}, {"number": "239", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "240", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "241", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "242", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "243", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "244", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "245", "ReferenceId": "24132290", "FullCitation": "Kandoth C, et al. Nature (2013) pmid: 24132290", "Include": "true"}, {"number": "246", "ReferenceId": "28039262", "FullCitation": "Dong ZY, et al. Clin. Cancer Res. (2017) pmid: 28039262", "Include": "true"}, {"number": "247", "ReferenceId": "16172461", "FullCitation": "Russo A, et al. J. Clin. Oncol. (2005) pmid: 16172461", "Include": "true"}, {"number": "248", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "249", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "250", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "251", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "252", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "253", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "254", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "255", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "256", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "257", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "258", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "259", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "260", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "261", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "262", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "263", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "264", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "265", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "266", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "267", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "268", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "269", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "270", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "271", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "272", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "273", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "274", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "275", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "276", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "277", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "278", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "279", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "280", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "281", "ReferenceId": "20639862", "FullCitation": "Ito S, et al. Nature (2010) pmid: 20639862", "Include": "true"}, {"number": "282", "ReferenceId": "21496894", "FullCitation": "Guo JU, et al. Cell (2011) pmid: 21496894", "Include": "true"}, {"number": "283", "ReferenceId": "32469185", "FullCitation": "Paik PK, et al. N. Engl. J. Med. (2020) pmid: 32469185", "Include": "true"}, {"number": "284", "ReferenceId": "31822497", "FullCitation": "Falchook GS, et al. Clin. Cancer Res. (2020) pmid: 31822497", "Include": "true"}, {"number": "285", "ReferenceId": "32328660", "FullCitation": "Shitara K, et al. Jpn. J. Clin. Oncol. (2020) pmid: 32328660", "Include": "true"}, {"number": "286", "ReferenceId": "30243800", "FullCitation": "Necchi A, et al. Eur. Urol. (2019) pmid: 30243800", "Include": "true"}, {"number": "287", "ReferenceId": "27764686", "FullCitation": "Levy A, et al. Eur. J. Cancer (2016) pmid: 27764686", "Include": "true"}, {"number": "288", "ReferenceId": "27354483", "FullCitation": "Yoshida T, et al. J. Clin. Oncol. (2016) pmid: 27354483", "Include": "true"}, {"number": "289", "ReferenceId": "25470694", "FullCitation": "Solomon BJ, et al. N. Engl. J. Med. (2014) pmid: 25470694", "Include": "true"}, {"number": "290", "ReferenceId": "23724913", "FullCitation": "Shaw AT, et al. N. Engl. J. Med. (2013) pmid: 23724913", "Include": "true"}, {"number": "291", "ReferenceId": "25264305", "FullCitation": "Shaw AT, et al. N. Engl. J. Med. (2014) pmid: 25264305", "Include": "true"}, {"number": "292", "ReferenceId": "25667280", "FullCitation": "Mazi\u00e8res J, et al. J. Clin. Oncol. (2015) pmid: 25667280", "Include": "true"}, {"number": "293", "ReferenceId": "25868855", "FullCitation": "Scheffler M, et al. Oncotarget (2015) pmid: 25868855", "Include": "true"}, {"number": "294", "ReferenceId": "24162815", "FullCitation": "Vaishnavi A, et al. Nat. Med. (2013) pmid: 24162815", "Include": "true"}, {"number": "295", "ReferenceId": "27343443", "FullCitation": "Schrock AB, et al. J Thorac Oncol (2016) pmid: 27343443", "Include": "true"}, {"number": "296", "ReferenceId": "26791794", "FullCitation": "Jorge SE, et al. Lung Cancer (2015) pmid: 26791794", "Include": "true"}, {"number": "297", "ReferenceId": "25971939", "FullCitation": "Paik PK, et al. Cancer Discov (2015) pmid: 25971939", "Include": "true"}, {"number": "298", "ReferenceId": "26892698", "FullCitation": "Mahjoubi L, et al. Invest New Drugs (2016) pmid: 26892698", "Include": "true"}, {"number": "299", "ReferenceId": "26845121", "FullCitation": "Benderra MA, et al. J Thorac Oncol (2016) pmid: 26845121", "Include": "true"}, {"number": "300", "ReferenceId": "25898962", "FullCitation": "Waqar SN, et al. J Thorac Oncol (2015) pmid: 25898962", "Include": "true"}, {"number": "301", "ReferenceId": "25898965", "FullCitation": "Mendenhall MA, et al. J Thorac Oncol (2015) pmid: 25898965", "Include": "true"}, {"number": "302", "ReferenceId": "25769807", "FullCitation": "Jenkins RW, et al. Clin Lung Cancer (2015) pmid: 25769807", "Include": "true"}, {"number": "303", "ReferenceId": "26729443", "FullCitation": "Awad MM, et al. J. Clin. Oncol. (2016) pmid: 26729443", "Include": "true"}, {"number": "304", "ReferenceId": "26724472", "FullCitation": "Zhang Y, et al. J Thorac Oncol (2016) pmid: 26724472", "Include": "true"}, {"number": "305", "ReferenceId": "23610116", "FullCitation": "Diamond JR, et al. J. Clin. Oncol. (2013) pmid: 23610116", "Include": "true"}, {"number": "306", "ReferenceId": "23598171", "FullCitation": "Moss\u00e9 YP, et al. Lancet Oncol. (2013) pmid: 23598171", "Include": "true"}, {"number": "307", "ReferenceId": "25971938", "FullCitation": "Frampton GM, et al. Cancer Discov (2015) pmid: 25971938", "Include": "true"}, {"number": "308", "ReferenceId": "25457019", "FullCitation": "Stein MN, et al. Eur. Urol. (2015) pmid: 25457019", "Include": "true"}, {"number": "309", "ReferenceId": "29863979", "FullCitation": "Migden MR, et al. N. Engl. J. Med. (2018) pmid: 29863979", "Include": "true"}, {"number": "310", "ReferenceId": "25891304", "FullCitation": "Postow MA, et al. N. Engl. J. Med. (2015) pmid: 25891304", "Include": "true"}, {"number": "311", "ReferenceId": "26027431", "FullCitation": "Larkin J, et al. N. Engl. J. Med. (2015) pmid: 26027431", "Include": "true"}, {"number": "312", "ReferenceId": "25399552", "FullCitation": "Robert C, et al. N. Engl. J. Med. (2015) pmid: 25399552", "Include": "true"}, {"number": "313", "ReferenceId": "24590637", "FullCitation": "Topalian SL, et al. J. Clin. Oncol. (2014) pmid: 24590637", "Include": "true"}, {"number": "314", "ReferenceId": "25795410", "FullCitation": "Weber JS, et al. Lancet Oncol. (2015) pmid: 25795410", "Include": "true"}, {"number": "315", "ReferenceId": "26028407", "FullCitation": "Brahmer J, et al. N. Engl. J. Med. (2015) pmid: 26028407", "Include": "true"}, {"number": "316", "ReferenceId": "26412456", "FullCitation": "Borghaei H, et al. N. Engl. J. Med. (2015) pmid: 26412456", "Include": "true"}, {"number": "317", "ReferenceId": "31100038", "FullCitation": "Sharma P, et al. J. Clin. Oncol. (2019) pmid: 31100038", "Include": "true"}, {"number": "318", "ReferenceId": "28131785", "FullCitation": "Sharma P, et al. Lancet Oncol. (2017) pmid: 28131785", "Include": "true"}, {"number": "319", "ReferenceId": "25452452", "FullCitation": "Motzer RJ, et al. J. Clin. Oncol. (2015) pmid: 25452452", "Include": "true"}, {"number": "320", "ReferenceId": "22658127", "FullCitation": "Topalian SL, et al. N. Engl. J. Med. (2012) pmid: 22658127", "Include": "true"}, {"number": "321", "ReferenceId": "20516446", "FullCitation": "Brahmer JR, et al. J. Clin. Oncol. (2010) pmid: 20516446", "Include": "true"}, {"number": "322", "ReferenceId": "26406148", "FullCitation": "Motzer RJ, et al. N. Engl. J. Med. (2015) pmid: 26406148", "Include": "true"}, {"number": "323", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "324", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "325", "ReferenceId": "22658128", "FullCitation": "Brahmer JR, et al. N. Engl. J. Med. (2012) pmid: 22658128", "Include": "true"}, {"number": "326", "ReferenceId": "26351349", "FullCitation": "Hamanishi J, et al. J. Clin. Oncol. (2015) pmid: 26351349", "Include": "true"}, {"number": "327", "ReferenceId": "31074244", "FullCitation": "Normann MC, et al. J Gynecol Oncol (2019) pmid: 31074244", "Include": "true"}, {"number": "328", "ReferenceId": "27269741", "FullCitation": "Antonia SJ, et al. Lancet Oncol. (2016) pmid: 27269741", "Include": "true"}, {"number": "329", "ReferenceId": "30110194", "FullCitation": "Janjigian YY, et al. J. Clin. Oncol. (2018) pmid: 30110194", "Include": "true"}, {"number": "330", "ReferenceId": "34843940", "FullCitation": "Tanizaki J, et al. Ann Oncol (2021) pmid: 34843940", "Include": "true"}, {"number": "331", "ReferenceId": "25482239", "FullCitation": "Ansell SM, et al. N. Engl. J. Med. (2015) pmid: 25482239", "Include": "true"}, {"number": "332", "ReferenceId": "27451390", "FullCitation": "Younes A, et al. Lancet Oncol. (2016) pmid: 27451390", "Include": "true"}, {"number": "333", "ReferenceId": "30361170", "FullCitation": "Hodi FS, et al. Lancet Oncol. (2018) pmid: 30361170", "Include": "true"}, {"number": "334", "ReferenceId": "27622997", "FullCitation": "Hodi FS, et al. Lancet Oncol. (2016) pmid: 27622997", "Include": "true"}, {"number": "335", "ReferenceId": "31562797", "FullCitation": "Larkin J, et al. N. Engl. J. Med. (2019) pmid: 31562797", "Include": "true"}, {"number": "336", "ReferenceId": "31562796", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2019) pmid: 31562796", "Include": "true"}, {"number": "337", "ReferenceId": "31427204", "FullCitation": "Motzer RJ, et al. Lancet Oncol. (2019) pmid: 31427204", "Include": "true"}, {"number": "338", "ReferenceId": "29562145", "FullCitation": "Motzer RJ, et al. N. Engl. J. Med. (2018) pmid: 29562145", "Include": "true"}, {"number": "339", "ReferenceId": "28778959", "FullCitation": "Kollipara R, et al. Oncologist (2017) pmid: 28778959", "Include": "true"}, {"number": "340", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "341", "ReferenceId": "26970723", "FullCitation": "Fehrenbacher L, et al. Lancet (2016) pmid: 26970723", "Include": "true"}, {"number": "342", "ReferenceId": "25428504", "FullCitation": "Herbst RS, et al. Nature (2014) pmid: 25428504", "Include": "true"}, {"number": "343", "ReferenceId": "26952546", "FullCitation": "Rosenberg JE, et al. Lancet (2016) pmid: 26952546", "Include": "true"}, {"number": "344", "ReferenceId": "25428503", "FullCitation": "Powles T, et al. Nature (2014) pmid: 25428503", "Include": "true"}, {"number": "345", "ReferenceId": "31780255", "FullCitation": "Geoerger B, et al. Lancet Oncol. (2020) pmid: 31780255", "Include": "true"}, {"number": "346", "ReferenceId": "26755520", "FullCitation": "McDermott DF, et al. J. Clin. Oncol. (2016) pmid: 26755520", "Include": "true"}, {"number": "347", "ReferenceId": "30918950", "FullCitation": "Hellmann MD, et al. Ann. Oncol. (2019) pmid: 30918950", "Include": "true"}, {"number": "348", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "349", "ReferenceId": "32240796", "FullCitation": "Schuler M, et al. Ann. Oncol. (2020) pmid: 32240796", "Include": "true"}, {"number": "350", "ReferenceId": "32877583", "FullCitation": "Wolf J, et al. N Engl J Med (2020) pmid: 32877583", "Include": "true"}, {"number": "351", "ReferenceId": "31776899", "FullCitation": "van den Bent M, et al. J. Neurooncol. (2020) pmid: 31776899", "Include": "true"}, {"number": "352", "ReferenceId": "31778267", "FullCitation": "Bang YJ, et al. Cancer Sci. (2020) pmid: 31778267", "Include": "true"}, {"number": "353", "ReferenceId": "30724423", "FullCitation": "Esaki T, et al. Cancer Sci. (2019) pmid: 30724423", "Include": "true"}, {"number": "354", "ReferenceId": "27157491", "FullCitation": "Muro K, et al. Lancet Oncol. (2016) pmid: 27157491", "Include": "true"}, {"number": "355", "ReferenceId": "26712084", "FullCitation": "Herbst RS, et al. Lancet (2016) pmid: 26712084", "Include": "true"}, {"number": "356", "ReferenceId": "27247226", "FullCitation": "Seiwert TY, et al. Lancet Oncol. (2016) pmid: 27247226", "Include": "true"}, {"number": "357", "ReferenceId": "27138582", "FullCitation": "Nanda R, et al. J. Clin. Oncol. (2016) pmid: 27138582", "Include": "true"}, {"number": "358", "ReferenceId": "31812554", "FullCitation": "Geoerger B, et al. Lancet Oncol. (2020) pmid: 31812554", "Include": "true"}, {"number": "359", "ReferenceId": "30922731", "FullCitation": "Makker V, et al. Lancet Oncol. (2019) pmid: 30922731", "Include": "true"}, {"number": "360", "ReferenceId": "29059635", "FullCitation": "Sch\u00f6ffski P, et al. Eur. J. Cancer (2017) pmid: 29059635", "Include": "true"}, {"number": "361", "ReferenceId": "30528315", "FullCitation": "Hellerstedt BA, et al. Clin Lung Cancer (2019) pmid: 30528315", "Include": "true"}, {"number": "362", "ReferenceId": "30718102", "FullCitation": "Nokihara H, et al. Clin Lung Cancer (2019) pmid: 30718102", "Include": "true"}, {"number": "363", "ReferenceId": "24002501", "FullCitation": "Elisei R, et al. J. Clin. Oncol. (2013) pmid: 24002501", "Include": "true"}, {"number": "364", "ReferenceId": "29972759", "FullCitation": "Abou_Alfa GK, et al. N. Engl. J. Med. (2018) pmid: 29972759", "Include": "true"}, {"number": "365", "ReferenceId": "28199818", "FullCitation": "Choueiri TK, et al. J. Clin. Oncol. (2017) pmid: 28199818", "Include": "true"}, {"number": "366", "ReferenceId": "32078813", "FullCitation": "Italiano A, et al. Lancet Oncol. (2020) pmid: 32078813", "Include": "true"}, {"number": "367", "ReferenceId": "27693535", "FullCitation": "Klempner SJ, et al. J Thorac Oncol (2017) pmid: 27693535", "Include": "true"}, {"number": "368", "ReferenceId": "21926191", "FullCitation": "Yakes FM, et al. Mol. Cancer Ther. (2011) pmid: 21926191", "Include": "true"}, {"number": "369", "ReferenceId": "25260782", "FullCitation": "Weber H, et al. J Biomol Screen (2014) pmid: 25260782", "Include": "true"}, {"number": "370", "ReferenceId": "23484006", "FullCitation": "Navis AC, et al. PLoS ONE (2013) pmid: 23484006", "Include": "true"}, {"number": "371", "ReferenceId": "26013381", "FullCitation": "Yeh I, et al. Nat Commun (2015) pmid: 26013381", "Include": "true"}, {"number": "372", "ReferenceId": "25534569", "FullCitation": "Lee YH, et al. Cancers (Basel) (2014) pmid: 25534569", "Include": "true"}, {"number": "373", "ReferenceId": "21540237", "FullCitation": "Torres KE, et al. Clin. Cancer Res. (2011) pmid: 21540237", "Include": "true"}, {"number": "374", "ReferenceId": "26432786", "FullCitation": "Sameni M, et al. Clin. Cancer Res. (2016) pmid: 26432786", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_04_19 14:18:36", "OpName": "Leah Commander, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Leah Commander, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "761x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "63 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease_ontology": "Unknown primary malignant neoplasm", "flowcell_analysis": "2000021269", "gender": "female", "pathology_diagnosis": "Malignant tumor", "percent_tumor_nuclei": "40", "pipeline_version": "v3.10.2", "purity_assessment": "47.8", "specimen": "ORD_1336448_02*US1284630.01", "study": "CLINICAL_HEME_COMPLETE", "test_request": "ORD_1336448_02", "test_type": "HemeComplete", "tissue_of_origin": "Mouth", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": [{"bait_set": "D2", "mean_exon_depth": "788.57", "name": "SQ_US1284630.01_1", "nucleic_acid_type": "DNA"}, {"bait_set": "R2", "mean_exon_depth": "509.65", "name": "SQ_US1284630.01_2", "nucleic_acid_type": "RNA"}]}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.1765", "cds_effect": "6554C>T", "depth": "742", "equivocal": "false", "functional_effect": "missense", "gene": "SPEN", "percent_reads": "17.65", "position": "chr1:16259289", "protein_effect": "S2185F", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0922", "cds_effect": "1384G>T", "depth": "998", "equivocal": "false", "functional_effect": "missense", "gene": "CIITA", "percent_reads": "9.22", "position": "chr16:11000733", "protein_effect": "A462S", "status": "unknown", "strand": "+", "transcript": "NM_000246", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1418", "cds_effect": "10231G>C", "depth": "656", "equivocal": "false", "functional_effect": "missense", "gene": "PRKDC", "percent_reads": "14.18", "position": "chr8:48711837", "protein_effect": "D3411H", "status": "unknown", "strand": "_", "transcript": "NM_006904", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.3245", "cds_effect": "2108G>C", "depth": "789", "equivocal": "false", "functional_effect": "missense", "gene": "SMO", "percent_reads": "32.45", "position": "chr7:128852036", "protein_effect": "R703P", "status": "unknown", "strand": "+", "transcript": "NM_005631", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0866", "cds_effect": "367C>G", "depth": "566", "equivocal": "false", "functional_effect": "missense", "gene": "IL7R", "percent_reads": "8.66", "position": "chr5:35867553", "protein_effect": "L123V", "status": "unknown", "strand": "+", "transcript": "NM_002185", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1003", "cds_effect": "3391G>T", "depth": "778", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB4", "percent_reads": "10.03", "position": "chr2:212251668", "protein_effect": "D1131Y", "status": "unknown", "strand": "_", "transcript": "NM_005235", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0781", "cds_effect": "56G>C", "depth": "64", "equivocal": "false", "functional_effect": "missense", "gene": "FBXO31", "percent_reads": "7.81", "position": "chr16:87417295", "protein_effect": "R19P", "status": "unknown", "strand": "_", "transcript": "NM_024735", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0577", "cds_effect": "1304A>G", "depth": "555", "equivocal": "false", "functional_effect": "missense", "gene": "FLT4", "percent_reads": "5.77", "position": "chr5:180052986", "protein_effect": "Y435C", "status": "unknown", "strand": "_", "transcript": "NM_002020", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1051", "cds_effect": "703G>A", "depth": "609", "equivocal": "false", "functional_effect": "missense", "gene": "TSHR", "percent_reads": "10.51", "position": "chr14:81574966", "protein_effect": "G235R", "status": "unknown", "strand": "+", "transcript": "NM_001018036", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0938", "cds_effect": "1943C>A", "depth": "821", "equivocal": "false", "functional_effect": "missense", "gene": "CIITA", "percent_reads": "9.38", "position": "chr16:11001292", "protein_effect": "A648E", "status": "unknown", "strand": "+", "transcript": "NM_000246", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1941", "cds_effect": "5297C>T", "depth": "1216", "equivocal": "false", "functional_effect": "missense", "gene": "MYST3", "percent_reads": "19.41", "position": "chr8:41790441", "protein_effect": "P1766L", "status": "unknown", "strand": "_", "transcript": "NM_006766", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1006", "cds_effect": "2992G>T", "depth": "666", "equivocal": "false", "functional_effect": "nonsense", "gene": "SMC3", "percent_reads": "10.06", "position": "chr10:112361823", "protein_effect": "E998*", "status": "unknown", "strand": "+", "transcript": "NM_005445", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.137", "cds_effect": "449T>A", "depth": "511", "equivocal": "false", "functional_effect": "missense", "gene": "SOCS1", "percent_reads": "13.7", "position": "chr16:11348887", "protein_effect": "L150Q", "status": "unknown", "strand": "_", "transcript": "NM_003745", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.053", "cds_effect": "19G>C", "depth": "887", "equivocal": "false", "functional_effect": "missense", "gene": "PDGFRA", "percent_reads": "5.3", "position": "chr4:55124954", "protein_effect": "A7P", "status": "unknown", "strand": "+", "transcript": "NM_006206", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0494", "cds_effect": "544C>T", "depth": "871", "equivocal": "false", "functional_effect": "nonsense", "gene": "HIST1H1D", "percent_reads": "4.94", "position": "chr6:26234618", "protein_effect": "Q182*", "status": "known", "strand": "_", "transcript": "NM_005320", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0522", "cds_effect": "3221G>T", "depth": "862", "equivocal": "false", "functional_effect": "missense", "gene": "NSD1", "percent_reads": "5.22", "position": "chr5:176638621", "protein_effect": "R1074L", "status": "unknown", "strand": "+", "transcript": "NM_022455", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0947", "cds_effect": "628G>C", "depth": "665", "equivocal": "false", "functional_effect": "missense", "gene": "MAPK1", "percent_reads": "9.47", "position": "chr22:22143079", "protein_effect": "D210H", "status": "unknown", "strand": "_", "transcript": "NM_002745", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.103", "cds_effect": "3694_3695GG>CT", "depth": "1010", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA1", "percent_reads": "10.3", "position": "chr17:41243853", "protein_effect": "G1232L", "status": "unknown", "strand": "_", "transcript": "NM_007294", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1315", "cds_effect": "3547G>T", "depth": "502", "equivocal": "false", "functional_effect": "missense", "gene": "SMARCA4", "percent_reads": "13.15", "position": "chr19:11143966", "protein_effect": "D1183Y", "status": "unknown", "strand": "+", "transcript": "NM_003072", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.5496", "cds_effect": "101G>A", "depth": "544", "equivocal": "false", "functional_effect": "missense", "gene": "FBXO11", "percent_reads": "54.96", "position": "chr2:48066788", "protein_effect": "S34N", "status": "unknown", "strand": "_", "transcript": "NM_025133", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0458", "cds_effect": "478G>T", "depth": "633", "equivocal": "false", "functional_effect": "missense", "gene": "FLT4", "percent_reads": "4.58", "position": "chr5:180057260", "protein_effect": "V160L", "status": "known", "strand": "_", "subclonal": "false", "transcript": "NM_002020", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1096", "cds_effect": "1901C>A", "depth": "520", "equivocal": "false", "functional_effect": "missense", "gene": "FLT4", "percent_reads": "10.96", "position": "chr5:180048661", "protein_effect": "A634D", "status": "unknown", "strand": "_", "transcript": "NM_002020", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1043", "cds_effect": "2643G>C", "depth": "585", "equivocal": "false", "functional_effect": "missense", "gene": "EPHA5", "percent_reads": "10.43", "position": "chr4:66213787", "protein_effect": "E881D", "status": "unknown", "strand": "_", "transcript": "NM_004439", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0967", "cds_effect": "1474C>T", "depth": "848", "equivocal": "false", "functional_effect": "nonsense", "gene": "TRAF3", "percent_reads": "9.67", "position": "chr14:103371888", "protein_effect": "Q492*", "status": "likely", "strand": "+", "transcript": "NM_003300", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1399", "cds_effect": "1022C>A", "depth": "636", "equivocal": "false", "functional_effect": "missense", "gene": "P2RY8", "percent_reads": "13.99", "position": "chrX:1584430", "protein_effect": "P341H", "status": "unknown", "strand": "_", "transcript": "NM_178129", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.4444", "cds_effect": "2440C>T", "depth": "450", "equivocal": "false", "functional_effect": "missense", "gene": "BRIP1", "percent_reads": "44.44", "position": "chr17:59793364", "protein_effect": "R814C", "status": "unknown", "strand": "_", "transcript": "NM_032043", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.122", "cds_effect": "314G>A", "depth": "967", "equivocal": "false", "functional_effect": "missense", "gene": "CD22", "percent_reads": "12.2", "position": "chr19:35823729", "protein_effect": "S105N", "status": "unknown", "strand": "+", "transcript": "NM_001771", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0983", "cds_effect": "708C>G", "depth": "946", "equivocal": "false", "functional_effect": "missense", "gene": "EPHB1", "percent_reads": "9.83", "position": "chr3:134670797", "protein_effect": "I236M", "status": "unknown", "strand": "+", "transcript": "NM_004441", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.2703", "cds_effect": "1106G>A", "depth": "518", "equivocal": "false", "functional_effect": "missense", "gene": "GPR124", "percent_reads": "27.03", "position": "chr8:37690536", "protein_effect": "R369Q", "status": "unknown", "strand": "+", "transcript": "NM_032777", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0968", "cds_effect": "601G>C", "depth": "775", "equivocal": "false", "functional_effect": "missense", "gene": "ALK", "percent_reads": "9.68", "position": "chr2:30142925", "protein_effect": "E201Q", "status": "unknown", "strand": "_", "transcript": "NM_004304", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1108", "cds_effect": "274G>C", "depth": "686", "equivocal": "false", "functional_effect": "missense", "gene": "HIST1H3B", "percent_reads": "11.08", "position": "chr6:26032015", "protein_effect": "A92P", "status": "unknown", "strand": "_", "transcript": "NM_003537", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.3619", "cds_effect": "718C>T", "depth": "970", "equivocal": "false", "functional_effect": "missense", "gene": "FRS2", "percent_reads": "36.19", "position": "chr12:69967926", "protein_effect": "P240S", "status": "unknown", "strand": "+", "transcript": "NM_006654", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1738", "cds_effect": "1969G>C", "depth": "650", "equivocal": "false", "functional_effect": "missense", "gene": "BRD4", "percent_reads": "17.38", "position": "chr19:15366186", "protein_effect": "E657Q", "status": "unknown", "strand": "_", "transcript": "NM_014299", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0987", "cds_effect": "2739C>A", "depth": "689", "equivocal": "false", "functional_effect": "missense", "gene": "LRP1B", "percent_reads": "9.87", "position": "chr2:141747132", "protein_effect": "S913R", "status": "unknown", "strand": "_", "transcript": "NM_018557", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1113", "cds_effect": "3622G>A", "depth": "665", "equivocal": "false", "functional_effect": "missense", "gene": "PLCG2", "percent_reads": "11.13", "position": "chr16:81990351", "protein_effect": "E1208K", "status": "unknown", "strand": "+", "transcript": "NM_002661", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1092", "cds_effect": "7G>A", "depth": "760", "equivocal": "false", "functional_effect": "missense", "gene": "HIST1H1C", "percent_reads": "10.92", "position": "chr6:26056650", "protein_effect": "E3K", "status": "unknown", "strand": "_", "transcript": "NM_005319", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1181", "cds_effect": "3020C>G", "depth": "686", "equivocal": "false", "functional_effect": "nonsense", "gene": "ABL1", "percent_reads": "11.81", "position": "chr9:133760697", "protein_effect": "S1007*", "status": "unknown", "strand": "+", "transcript": "NM_005157", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.5307", "cds_effect": "2069G>A", "depth": "456", "equivocal": "false", "functional_effect": "missense", "gene": "WDR90", "percent_reads": "53.07", "position": "chr16:706404", "protein_effect": "R690Q", "status": "unknown", "strand": "+", "transcript": "NM_145294", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0665", "cds_effect": "526A>G", "depth": "887", "equivocal": "false", "functional_effect": "missense", "gene": "EPHA5", "percent_reads": "6.65", "position": "chr4:66467743", "protein_effect": "T176A", "status": "unknown", "strand": "_", "transcript": "NM_004439", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0911", "cds_effect": "158C>T", "depth": "593", "equivocal": "false", "functional_effect": "missense", "gene": "SUZ12", "percent_reads": "9.11", "position": "chr17:30264423", "protein_effect": "S53L", "status": "unknown", "strand": "+", "transcript": "NM_015355", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.2111", "cds_effect": "375G>T", "depth": "559", "equivocal": "false", "functional_effect": "splice", "gene": "TP53", "percent_reads": "21.11", "position": "chr17:7579312", "protein_effect": "splice site 375G>T", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1053", "cds_effect": "121G>T", "depth": "750", "equivocal": "false", "functional_effect": "nonsense", "gene": "KEAP1", "percent_reads": "10.53", "position": "chr19:10610589", "protein_effect": "E41*", "status": "likely", "strand": "_", "transcript": "NM_012289", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.227", "cds_effect": "662G>A", "depth": "771", "equivocal": "false", "functional_effect": "missense", "gene": "JUN", "percent_reads": "22.7", "position": "chr1:59248081", "protein_effect": "R221Q", "status": "unknown", "strand": "_", "transcript": "NM_002228", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.3824", "cds_effect": "3332C>T", "depth": "782", "equivocal": "false", "functional_effect": "missense", "gene": "BCORL1", "percent_reads": "38.24", "position": "chrX:129150080", "protein_effect": "T1111M", "status": "unknown", "strand": "+", "transcript": "NM_021946", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.5088", "cds_effect": "1591G>A", "depth": "627", "equivocal": "false", "functional_effect": "missense", "gene": "CIC", "percent_reads": "50.88", "position": "chr19:42794511", "protein_effect": "A531T", "status": "unknown", "strand": "+", "transcript": "NM_015125", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1285", "cds_effect": "4324G>T", "depth": "1136", "equivocal": "false", "functional_effect": "missense", "gene": "MYST3", "percent_reads": "12.85", "position": "chr8:41791414", "protein_effect": "A1442S", "status": "unknown", "strand": "_", "transcript": "NM_006766", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0582", "cds_effect": "7732A>G", "depth": "911", "equivocal": "false", "functional_effect": "missense", "gene": "MKI67", "percent_reads": "5.82", "position": "chr10:129902372", "protein_effect": "I2578V", "status": "unknown", "strand": "_", "transcript": "NM_002417", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.3022", "cds_effect": "9102G>T", "depth": "675", "equivocal": "false", "functional_effect": "missense", "gene": "PCLO", "percent_reads": "30.22", "position": "chr7:82580802", "protein_effect": "E3034D", "status": "unknown", "strand": "_", "transcript": "NM_014510", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1464", "cds_effect": "368G>C", "depth": "717", "equivocal": "false", "functional_effect": "missense", "gene": "TAF1", "percent_reads": "14.64", "position": "chrX:70587976", "protein_effect": "R123T", "status": "unknown", "strand": "+", "transcript": "NM_138923", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1367", "cds_effect": "229G>A", "depth": "717", "equivocal": "false", "functional_effect": "missense", "gene": "BCORL1", "percent_reads": "13.67", "position": "chrX:129146977", "protein_effect": "D77N", "status": "unknown", "strand": "+", "transcript": "NM_021946", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1029", "cds_effect": "560C>A", "depth": "544", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK2", "percent_reads": "10.29", "position": "chr9:87325683", "protein_effect": "A187E", "status": "unknown", "strand": "+", "transcript": "NM_006180", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.3601", "cds_effect": "2983C>G", "depth": "983", "equivocal": "false", "functional_effect": "missense", "gene": "PCLO", "percent_reads": "36.01", "position": "chr7:82763883", "protein_effect": "P995A", "status": "unknown", "strand": "_", "transcript": "NM_014510", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.5842", "cds_effect": "2468C>T", "depth": "1027", "equivocal": "false", "functional_effect": "missense", "gene": "ZNF217", "percent_reads": "58.42", "position": "chr20:52192835", "protein_effect": "P823L", "status": "unknown", "strand": "_", "transcript": "NM_006526", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0995", "cds_effect": "3593C>A", "depth": "774", "equivocal": "false", "functional_effect": "missense", "gene": "LRP1B", "percent_reads": "9.95", "position": "chr2:141660662", "protein_effect": "S1198Y", "status": "unknown", "strand": "_", "transcript": "NM_018557", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1028", "cds_effect": "310G>T", "depth": "749", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB3", "percent_reads": "10.28", "position": "chr12:56478854", "protein_effect": "V104L", "status": "known", "strand": "+", "transcript": "NM_001982", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1062", "cds_effect": "88G>T", "depth": "471", "equivocal": "false", "functional_effect": "missense", "gene": "SOX2", "percent_reads": "10.62", "position": "chr3:181430236", "protein_effect": "A30S", "status": "unknown", "strand": "+", "transcript": "NM_003106", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0534", "cds_effect": "5651C>A", "depth": "281", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH1", "percent_reads": "5.34", "position": "chr9:139395287", "protein_effect": "P1884Q", "status": "unknown", "strand": "_", "transcript": "NM_017617", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0887", "cds_effect": "312G>C", "depth": "620", "equivocal": "false", "functional_effect": "missense", "gene": "IL7R", "percent_reads": "8.87", "position": "chr5:35867498", "protein_effect": "K104N", "status": "unknown", "strand": "+", "transcript": "NM_002185", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0948", "cds_effect": "4249G>T", "depth": "865", "equivocal": "false", "functional_effect": "missense", "gene": "TET2", "percent_reads": "9.48", "position": "chr4:106193787", "protein_effect": "V1417F", "status": "known", "strand": "+", "transcript": "NM_001127208", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0617", "cds_effect": "775G>T", "depth": "567", "equivocal": "false", "functional_effect": "missense", "gene": "PPP2R1A", "percent_reads": "6.17", "position": "chr19:52716331", "protein_effect": "V259F", "status": "unknown", "strand": "+", "transcript": "NM_014225", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.2936", "cds_effect": "1273A>G", "depth": "654", "equivocal": "false", "functional_effect": "missense", "gene": "POT1", "percent_reads": "29.36", "position": "chr7:124481123", "protein_effect": "T425A", "status": "unknown", "strand": "_", "transcript": "NM_015450", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.5371", "cds_effect": "2939T>A", "depth": "916", "equivocal": "false", "functional_effect": "missense", "gene": "ASXL1", "percent_reads": "53.71", "position": "chr20:31023454", "protein_effect": "I980N", "status": "unknown", "strand": "+", "transcript": "NM_015338", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.0889", "cds_effect": "1034C>T", "depth": "461", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB4", "percent_reads": "8.89", "position": "chr2:212576865", "protein_effect": "A345V", "status": "unknown", "strand": "_", "transcript": "NM_005235", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1111", "cds_effect": "1351G>C", "depth": "936", "equivocal": "false", "functional_effect": "missense", "gene": "TNFAIP3", "percent_reads": "11.11", "position": "chr6:138199933", "protein_effect": "E451Q", "status": "unknown", "strand": "+", "transcript": "NM_006290", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.085", "cds_effect": "91G>T", "depth": "353", "equivocal": "false", "functional_effect": "nonsense", "gene": "HGF", "percent_reads": "8.5", "position": "chr7:81392186", "protein_effect": "G31*", "status": "unknown", "strand": "_", "transcript": "NM_000601", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.13", "cds_effect": "3395C>A", "depth": "777", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB4", "percent_reads": "13.0", "position": "chr2:212251664", "protein_effect": "P1132H", "status": "unknown", "strand": "_", "transcript": "NM_005235", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1669", "cds_effect": "142C>T", "depth": "677", "equivocal": "false", "functional_effect": "missense", "gene": "ARID2", "percent_reads": "16.69", "position": "chr12:46123876", "protein_effect": "H48Y", "status": "unknown", "strand": "+", "transcript": "NM_152641", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"allele_fraction": "0.1033", "cds_effect": "979G>T", "depth": "949", "equivocal": "false", "functional_effect": "missense", "gene": "FAM123B", "percent_reads": "10.33", "position": "chrX:63412188", "protein_effect": "G327C", "status": "unknown", "strand": "_", "transcript": "NM_152424", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": {"copy_number": "10", "equivocal": "false", "gene": "MET", "number_of_exons": "20 of 20", "position": "chr7:116297505_116484285", "ratio": "2.2", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}}, "rearrangements": {"rearrangement": [{"description": "ETV6(NM_001987) rearrangement intron 5", "equivocal": "false", "in_frame": "unknown", "other_gene": "AUTS2", "pos1": "chr12:12023286_12023586", "pos2": "chr7:69790453_69790649", "status": "likely", "supporting_read_pairs": "41", "targeted_gene": "ETV6", "type": "truncation", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}, {"description": "ETV6(NM_001987) inversion intron 5 _ intron 5", "equivocal": "false", "in_frame": "unknown", "other_gene": "ETV6", "pos1": "chr12:12030985_12031188", "pos2": "chr12:12033621_12033982", "status": "likely", "supporting_read_pairs": "16", "targeted_gene": "ETV6", "type": "truncation", "dna_evidence": {"sample": "SQ_US1284630.01_1"}}]}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "62.72", "status": "high", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}